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ABSTRACT
Recent clinical studies have highlighted the effectiveness of
immunotherapy for Gram-negative bacteraemia in humans. Studies in
America, undertaken on patients with Gram-negative bacteraemia, have
shown that mortality was reduced by virtually 50% in patients who
received specific antiendotoxin antiserum. In India, mortality from
pseudomonas septicaemia was significantly reduced by the
administration of small quantities of a anti-pseudomonas
immunoglobulin.
The antibodies in those studies were raised by vaccination of healthy
volunteers with heat-killed Gram-negative bacteria or vaccines
containing endotoxin. Adverse side effects in volunteers as well as
logistic and legal problems make it difficult to produce antiserum on
a large scale, in this manner.
In Israel, S.L. Gaffin and coworkers found that approximately 7% of
plasma units in a blood bank had antiendotoxin antibody concentrations
of 40 ).1g/m1 or greater. This high titre human plasma significantly
protected cats from lethal endotoxic shock secondary to haemorrhage.
The immunoprecipitin technique used by them to measure antiendotoxin
antibody concentrations was unsuitable for screening large numbers of
blood samples. To overcome this problem we have devised an
enzyme-linked imounosorbent assay (ELISA) for determining the level of
antiendotoxin immunoglobulin G in human plasma. The assay, which is
suitable for large scale use, was found to be specific for
antiendotoxin antibodies. It was calibrated using a serum sample of
specific antibody concentration as determined by an ilununoprecipitin
assay.
Serum samples found to be high in antiendotoxin titres (> 40_ug/m1)
were tested for their specificity towards endotoxins from 12 bacterial
iv
strains and species. While each sample was found to have its own
characteristic specificities, most were found to react strongly with
Sh. flexneri, S. typhimurium and S. enteritidis.
The Natal Blood Transfusion Service has found that in Natal, blood
units containing high concentrations of specific antibodies occur with
a frequency of 3,6% among all White donors and 10,35% among all
African donors. They found that African females, in turn, had almost
twice the frequency of high titre serum as African males. In this
study, Indian female hospital patients did not have a statistically
higher frequency of high-titre serum than Indian male patients.
Blood units donated to the Natal Blood Transfusion Service are now
routinely screened by ELISA for antiendotoxin antibodies and those
units with high concentrations (> 40 ug/ml) of antibody were pooled
and fractionated to obtain a gamma globulin, Lot LG-l. The binding
capacity of the LG-1 antibodies towards 12 endotoxins was examined.
Binding was found to be highest with endotoxin from Sh. flexneri, S.
abortus equi and S. typhimurium and intermediate with S. enteritidis 
and E.coli 026:B6. Binding with the other endotoxins tested was
relatively low. Differential absorption experiments showed that LG-1
was made up of a mixture of cross-reacting as well as specific
antibodies For example, the antibodies binding Sh. flexneri 
endotoxin were mainly specific. Those binding E. coli 026:B6
endotoxin were specific and cross-reacting in almost equal
proportions. Antibodies to the endotoxins from the salmonella strains
tested were mainly cross-reacting. The specificities of the LG-1
antibodies towards endotoxins from the various Gram-negative bacteria
did not in most cases reflect the incidence of these organisms in
blood cultures taken from hospital patients.
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The activity of LG-1 antibodies was compared to that of normal human
immunoglobulin preparations obtained from the National Blood
Fractionation Centre, Pinetown and to an anti-pseudomonas
immunoglobulin prepared by Wellcome Laboratories, England. The
binding capacity of the antibodies in the standard globulin
preparations towards most of the endotoxins tested was less than 15%
of that of the LG-1 antibodies. The anti-pseudomonas immunoglobulin
was shown to bind poorly to most of the endotoxins tested in
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Endotoxin, also referred to as pyrogen or lipopolysaccharide (LPS) is
a poison found as an integral part of the cell surface of
Gram-negative bacteria (1) . Such bacteria and therefore endotoxin are
always present and contained within the intestines. In normal
individuals, small quantities of endotoxin leak into the portal
circulation and are readily cleared by the reticuloendothelial system
in the liver (2) . If however, the permeability of the intestines is
altered or liver function is impaired, then endotoxaemia occurs,
resulting in pathological changes which may ultimately culminate in
shock and death. Endotoxin may also enter the circulation through a
septic focus, resulting from, for example, wounds and burns. Patients
whose defence mechanisms are compromised by diseases such as leukaemia
and lymphoma or by treatment with irmiunosuppressive drugs are
particularly susceptible to bacterial infections (3) . Even with the
best available treatment, septicaemia is a major cause of death in
patients with cancer (4) .
In the United States, the frequency of Gram-negative bacteraemia has
been estimated at approximately 1 per 100 hospital patients, with
fatality rates of 30-50% and is thus a major health problem (5) .
Different types of treatment have been used in an attempt to lower the
mortality from Gram-negative bacteraemia. Despite the use of powerful
antibiotics, high doses of adrenocorticosteroids, modern life-support
systems and sophisticated monitoring devices, the incidence of
bacteraemia continues to increase with sustained high mortality
rates (6) .
It has long been recognized that tolerance to some of the biological
effects of endotoxin can be induced by vaccination of animals with
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endotoxin, or killed Gram-negative bacteria (7 / 8) . Enhanced resistance
to endotoxin is also found after infections with Gram-negative
bacteria. Furthermore, the passive transfer of serum from
endotoxin-tolerant animals is known to protect recipients against the
lethal effects of endotoxin
(9,10). 
Fever, the local Shwartzman
reaction, intravascular coagulation, hypotension and even death from
endotoxin have been prevented in animals by the use of antiserum.
Much of this work has been reviewed by Braude (11) . Specific antibody
present in the antiserum is thought to be resposible for the
inactivation of endotoxin.
In 1973, it was found that human antiserum could also confer passive
immunity to the effects of endotoxin in animals (12) . In recent years
clinical studies have highlighted the effectiveness of immunotherapy
for Gram-negative bacteraemia in humans. Studies in America,
undertaken in patients severely ill with Gram-negative bacteraemia,
have shown that mortality was reduced by virtually fifty percent in
those patients who received specific antiendotoxin antiserum
(13-15).
In India, where the risk of death from pseudomonas septicaemia
resulting from severe burns is high, it was found that mortality was
very significantly reduced by the administration of small quantities
of an anti-pseudomonas immunoglobulin (16) .
These noteworthy studies have however some serious limitations. The
antibodies were raised by vaccination of healthy volunteers with
heat-killed Gram-negative bacteria or vaccines containing LPS-(13-16) .
Injection of humans with potentially dangerous substances even under
controlled conditions is undesirable and is reported to have led to
local and/or systemic reactions in some volunteers (17) . Thus, the
side-effects in immunized volunteers as well as logistic problems make
it difficult to produce antiserum on a large scale, in this manner.
As a way of overcoming these problems, S.L. Gaffin and coworkers in
Israel, screened units of plasma in a blood bank to find samples rich
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in antiendotoxin antibodies (18) . They found that approximately 7% of
these units had antiendotoxin antibody concentrations of 40,,ug/m1 or
greater. The high titre human plasma, after absorption of
agglutinins, was used to treat cats who were in lethal haemorrhagic
shock. Survival was markedly improved in those cats infused with the
antiendotoxin antibody-rich plasma compared to that in controls.
The above work has been subsequently extended in South Africa in
conjunction with the Natal Blood Transfusion Service. In the Israeli
study, an immunoprecipitin assay was used to measure the antiendotoxin
antibody levels in blood units. This technique is unsuitable for
screening large numbers of blood samples on a routine basis since it
takes two and a half days in order to complete the assay and only a
few samples can be conveniently handled at a time. To overcome this
problem we attempted to devise an enzyme-linked immunosorbent assay
(ELISA) for determining the level of antiendotoxin antibodies in human
plasma. The technique of ELISA, pioneered by Engvall and
PerImann
(19-21) 
and Van Weemen and Schuurs (22) has been adapted for
use with disposable microtitre plates providing an assay system which
is convenient for large scale use (23) . It has the added advantage of
being economical since only small volumes of reagents are required.
The reagents are relatively cheap and stable, having a long half-life.
ELISA compares very favourably in sensitivity to radioimmunoassay and
gives results which may be determined visually or with simple
photometers (23) . in the laboratories of the Natal Blood Transfusion
Service, ELISA is used extensively to measure a range of antibodies
and antigens, for example, serum ferritin, 0L-fetoprotein,
anti-rubella, anti-tetanus etc (24) .
Thus the purpose of this study was to develop an ELISA for the
screening of human blood for antiendotoxin antibodies and to
investigate the specificity of the antibodies according to their
ability to react with various pure endotoxins obtained from several




2.1 THE STRUCTURE OF THE GRAM-NEGATIVE BACTERIAL CELL WALL
Bacteria are divided into two major groups depending on their reaction
to the Gram staining procedure (25) . Cells are stained with crystal
violet and iodine and then washed with an organic solvent such as
alcohol. The latter step decolourizes Gram-negative bacteria but not
Gram-positive bacteria. These reactions, in turn, depend on the
structure and chemistry of the cell walls.
Gram-negative organisms have a thin peptidoglycan layer adjacent to
the outer surface of the cell membrane
(26,27). 
Other substances lie
outside this peptidoglycan layer; lipoprotein serves to cross-link
the peptidoglycan with an outer membrane. Associated with the outer
membrane is the lipopolysaccharide which contributes most to the
uniqueness of the Gram-negative cell wall. A diagrammetic
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Figure 1. A model of the Gram-negative cell envelope
(25)
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Gram-positive organisms, such as the Staphylococci, Streptococci,
Clostridia and Bacilli, have much thicker multi-layered peptidoglycan
coats to which polysaccharides are covalently bound (28) . Complex
polymers of teichoic acids make up 20 to 50% of the dry weight of the
Gram-positive cell walls.
The lipopolysaccharide or endotoxin is thus only found in
Gram-negative organi s ms, where it forms an integral part of the cell
surface and as such it is mainly released when the cells are
lysed (29) . Exotoxins on the other hand, are protein in nature and are
secreted by living cells, both Gram-positive and Gram-negative (30) .
Tetanus toxin, for example, is one of the most poisonous exotoxins
known.
2.2 THE CHEMICAL STRUCTURE OF ENDOTOXIN
2.2.1 Introduction
Endotoxins from different groups of Gram-negative bacteria share a
common structural basis (29) . These macromolecules, the molecular
weights of which vary from 400,000 to 4,000,000 Daltons, are made up
of three major components, lipid A, core polysaccharide and the "0"
antigens.
The elucidation of the structure of lipopolysaccharides has been
advanced by the use of rough (R) mutants that are defective in the
synthesis of the complete lipopolysaccharide
(31)
 . Such R mutants have
been isolated from strains of various Gram-negative species including
Escherichia, Salmonella and Shigella.
Many procedures have been developed for the extraction of endotoxin
from bacterial cell walls. The most widely used techniques are
adaptations of either the trichloroacetic acid (TCA) procedure of
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Boivin and mesrobeanu (32) or the hot aqueous phenol extraction
procedure of Westphal and colleagues (33) .
The TCA procedure yields complexes of endotoxin containing
lipopolysaccharide and protein while the phenol procedure results in a
relatively protein free preparation of LPS. Standard endotoxin
preparations with well characterized biological and chemical
properties are now commercially available and their use is intended to
avoid problems with reproducibility among laboratories using
endotoxins (34) .
The structure of each of the three major components of
lipopolysaccharide will be examined.
2.2.2 Lipid A 
Lipid A has been isolated from mutant bacterial strains having
endotoxins containing only lipid A and KDO (2-keto-3-deoxyoctonate), a
trisaccharide of which normally links lipid A to the core region of
endotoxin (31) . Preparations of lipid A are also obtained from
lipopolysaccharides by acid hydrolysis, which cleaves the bonds
between lipid A and KDO. Lipid A contains glucosamine, phosphate and
long chain fatty acids. It is an unusual phospholipid in that
glucosamine and not glycerol forms the core (29) .
Salmonella lipid A, which has been extensively studied, has a backbone
of a p1,6-linked D-glucosamine disaccharide, which is phosphorylated
in positions 1 and 4' (1) . These phospate groups are partially
substituted by 4-amino-4-deoxy-L-arabinosyl and phosphorylethanolamine
residues. The backbone structure is illustrated in Figure 2, which




Figure 2. The glucosamine disaccharide structure, showing the
p1,6 linkage and sugar numbering system.
The amino groups of the disaccharide are acylated by
p-hydroxymyristic acid (3-hydroxytetradecanoic acid), which is a
14 - carbon fatty acid present specifically in enterobacterial lipid A
as well as in Pseudomonas. p-hydroxy fatty acids containing between
10 and 17 carbon atoms are found in other bacterial species (29) .
The hydroxyl groups at positions 3,4 and 6' of the glucosamine
disaccharide are esterified by a range of long chain fatty acids, e.g.
lauric, palmitic and 3-myristoxymyristic acid (29) . The disaccharide
subunits are linked to each other through phosphodiester bridges or
pyrophosphate linkages. Lipid A is associated with hydrophobic
regions of the outer membrane and in this way binds the LPS to the
cell membrane (26) .






















compared and found to share the basic structural features described
above, with only limited variability; e.g., the types of fatty acids
present (1) . Figure 3 from Ltideritz and coworkers illustrates the









Figure 3. Proposed structure of a lipid A unit of the Salmonella minnesota R595
glycolipid with an attached KDD trisaccharide. The three
fatty-acid residues shown are linked in an unknown distribution
to the hydroxyl groups of ( Sy glucosamine residues available
at positions 3, 4, and 6"
2.2.3 Core polysaccharide
Lipid A is linked to the core region by means of a trisaccharide of
KDO, 2-keto-3-deoxyoctonate (29) . Other components of the "core", from
varying species and strains, include heptose, phosphate, ethanolamine
and the hexoses, galatose, glucose and N-acetyl gluocosamine.
An inner core comprising KDO, heptose phosphate and ethanolamine is
assembled and linked to the three hexoses which are said to form the
outer core.
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The core polysaccharide structure has been studied in different
salmonella mutants which lack specific enzyme(s) so that synthesis of
the core remains incomplete (29) . Chemotype Rd of salmonella LPS
contains only KDO and heptose, while in chemotype Rc glucose is added
to this backbone. In chemotype b galactose is further incorporated
and finally the core of phenotype Ra is synthesized in full. This is





















N-acetyl glucosamine —glucose--galactose--glocose--heptose phosphate
gala( tose- heptose phosphate
N-at etyl osaminc Wucow— gala( l ow – hoptose phosphate
gala( Lose—heptose phosphate
Figure 4. The core polysaWNrides of chemotypes Rd, Rc, Rb and Ra of
Salmonella LPS"')
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All salmonella species have been found to synthesize LPS with a
polysaccharide core basically structured as described above. Same
variability in the core structure of LPS from the other species has
been reported (1) . However, this variability is low compared to that
of the "0" side chains.
2.2.4 "0" antigens 
The second polysaccharide component of LPS consists of the
"0"-specific chains, which are polymers of oligosaccharide repeating
units making up the outermost part of the LPS molecule (29) . These
oligosaccharide units contain usually between 3 to 5 sugars each and
often include relatively unusual sugars such a fucose, rhamnose,
paratose, abequose, colitose and tyvelose. When LPS of different
origin is examined much variability is found in the structure of the
"0" specific chains (1) . The nature of the individual sugars, their
sequence and the type of linkages and substitutions vary for LPSs from
different bacterial strains. Table 1 shows the structure of the
repeating oligosaccharide units in some Gram-negative bacteria.
1 1
Table 1 
Composition of repeating oligosaccharide units in certain
Gram-negative bacteria.
Bacteria Structure of Oligosaccharide Unit  Group or Serogroup
of -Tyv
Salmonella typhosa (29) 2 -- (0)-Man-1,4-Rha-1,3 ck-Gal-1 D
cd, -Abe cl-Glc
t 1,
Salmonella typhimurium (29) 2 —d —Mln -1,4 -Rha ol-Gal -1
4
A c i
Shigella flexneri (29) 	6---Glc Nac-1,2—Rha-1,4—Rha 1 2a
Escherichia coli(35) 1,2)man  1,2 ) Man _4
1 	08
cd.
Escherichia coli  ( 35) 	Nac Gal 1 1 4) L Rha 1 	075
c4 41,4 c4
Man
Glc = glucose; Gal = galactose; Rha = rhamnose; Man = mannose;






In summary, Figure 5 diagrammatically represents the characteristic
structural features of a typical salmonella LPS, showing the Lipid A,
core polysaccharide and "0" antigens.
0-Specific Chain JL Core Lipid A               
                          
Polysaccharide J-                                   
0 Monosaccharide , • Phosphate , Ethanolamine
Long Chain( Hydroxy Fatty Acid
Figure 5. Schematic structure of a salmonella lipopolysaccharide (1) .
The component of LPS which varies least in composition in different
Gram-negative bacterial species is lipid ItIt is this region
which has now been shown to be responsible for the toxicity of the LPS
molecule. It is suggested that the toxic component is associated with
the acylated central disaccharide.
Free lipid A has been tested for endotoxic activity by means of mouse
lethality, pyrogenicity, bone marrow necrosis, Limulus gelation and
complement inactivation studies (31) . Ltderitz and coworkers report
that their results "strongly indicate that lipid A represents the
biologically active centre in endotoxic lipopolysaccharides and that
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the polysaccharide component acts as a solubilizing carrier that can
be replaced by other non covalently bound carriers like serum
albumin". Thus, the "0" antigens are not directly involved in the
endotoxic activity but are thought instead to protect the bacteria
from attack by host enzymes and from ingestion by host phagocytic
cells. The protection is expected to be enhanced by the presence of
relatively uncommon "exotic" sugars (36) . Lipid A is poorly antigenic
while core polysaccharide is highly antigenic (11) . Nevertheless
anti-lipid A antibodies have been measured in, for example, patients
with urinary tract infections; the titres are said to be caused by
immunogenically active lipid A in the body (37) .
2.3 THE BIOLOGICAL EFFECTS OF ENDOTOXINS
The effects of endotoxins are widespread and varied. Some of the
principal actions are outlined below.
2.3.1 Hypotension 
High levels of circulating endotoxin cause a series of haemodynamic
changes which ultimately lead to hypotension. These are summarized
below.
(a) Endotoxin causes the release of vasoactive agents such as
catecholamines, prostaglandins, histamine, serotonin and
kinins (38-42).
(b) These vasoactive agents bring about the local contraction of
neighbouring capillary endothelial cells away from each other
forming "holes" in the capillary walls and directly damaging the
cells leading to their vacuolisaton
(43-46)
 . The pore size in the
endothelium is altered and this subsequently allows the escape of
plasma and red cells.
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(c) This epithelial damage results in increased permeability to blood
components and consequent oedema and hypovolaemia.
Endothelial damage in the lungs results in pulmonary oedema so
that proper gas exchange is impared - "shock lung" (47-50) .
Similarly, in the case of intestinal membranes, endothelial
damage leads to gastrointestinal bleeding (48) .
(d) This plasma loss leads to haemoconcentration with increased blood
viscosity (51) .
(e) Venous return is reduced. This is due to loss of plasma as well
as to vasoconstriction of central and hepatic veins in turn
leading to the accumulation of blood in the splanchnic region or
"splanchnic pooling" (51,52) . However, Guntheroth and coworkers
find that this hepatic trapping of blood seems in dogs to last
only the first 30 minutes after intravenous injection of
endotoxin (53) .
(f) The above events lead to a reduction in cardiac output and
subsequent hypotension. The fall in cardiac output results in
reduced oxygen supply to the tissues (54-56) . Acidosis results
with increased plasma lactate (55,57-59) .
(g) Endogenous opiates are released by the action of endotoxins and
may be responsible for further reducing blood pressure. The
endogenous opiate p-endorphin is stored with pituitary
adrenocorticotrophin, ACTH. Since endotoxins cause the secretion
of ACTH, it is considered likely that endotoxin also causes
release of pituitary p-endorphin at the same time (60) . Naloxone,
a specific opiate-antagonist, is found to be effective in
reversing endotoxin-induced hypotension in rats
(61,62)
. Naloxone




Under the above conditions electrolyte balance is disturbed (64) . The
concentration of potassium in the plasma is increased while
intracellular levels are decreased. The intracellular concentration
of sodium is increased.
All these effects contribute towards the deterioration of lysosomal
membranes and subsequent release of proteinases and other hydrolytic





The pyrogenic properties of endotoxins have been recognised for many
years. The fever which results after intravenous injection of
endotoxin is thought to be mediated by a protein, "endogenous pyrogen"
released from neutrophils or monocytes upon activation by
endotoxin (67) . Endogenous pyrogen in turn stimulates the temperature
regulation centres in the hypothalamus
(11,68)
. Moreover, endotoxin
itself appears to be capable of causing fever directly since when
micro-injected into the anterior hypothalmic preoptic region, fever
can be caused by a 100 times lower dose than when injected
intravenously(69).
It has been suggested that humans are much more sensitive to the
pyrogenic action of endotoxin than other animals, for example, the
same febrile response in rabbits and humans with S. typhosa endotoxin
requires 10 times as much endotoxin (0.05 Jag/kg body weight) in the
rabbit as in man (0.005 iug/kg body weight)
(70) . Other studies have
found rabbits to be equal or several times more responsive than
man
(67)
Detailed studies of fever after injection of endotoxin have been
carried out in rabbits (29 ' 67) . After intravenous injection of 0,1 pg
endotoxin, there is a variable latent period of 10 to 20 minutes
before the onset of a biphasic fever, with peaks at about 70 minutes
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and at about 3 hours. The second peak alone is dose dependent and is
not caused by smaller doses of endotoxin.
Skarnes and coworkers report endotoxin-induced biphasic fevers in
sheep (71) . Assays of plasma obtained during fever episodes show a
marked increase in prostaglandin E (PGE) during the initial phase of
fever only. Indomethacin, an inhibitor of prostaglandin metabolism,
is shown to block fever responses to both endotoxin and endogenous
pyrogen. These results implicate PGE as the mediator of the first
phase of endotoxin induced fever and also suggest that prostaglandins
may be involved in mediating the second phase of fever, associated
with circulating endogenous pyrogen.
2.3.3 Disseminated intravascular coagulation
The observations of Sanarelli and others of the effects of two
injections of culture filtrates from Gram-negative organisms first
demonstrated what is now known to be the ability of endotoxin to
produce tissue injury through initiation of coagulative
changes (72-75) . These early observations were extended and resulted
in two widely used experimental models : the local and the generalized
Shwartzman reactions.
In order to produce these reactions in experimental animals, two
injections of endotoxin are given 12 to 18 hours apart (29) . For the
local Shwartzman reaction the first dose is given intradermally and
the second intravenously. Within a few hours after the second dose an
area of haemorrhagic necrosis is seen at the site of the first
injection.
For the generalized Shwartzman reaction both endotoxin injections are
given intravenously. Within a few hours of the second dose, the
animals develop bilateral cortical necrosis of the kidneys
(44)
17
An intravenous dose of endotoxin causes intravascular coagulation and
subsequent production of fibrin polymers. In the local Shwartzman
reaction these polymers are trapped in skin vessels which have been
injured by an inflammatory reaction caused by the intradermal dose of
endotoxin. No renal cortical necrosis is seen because most of the
circulating fibrin is cleared by the reticuloendothelial system.
However in the generalized Shwartzman reaction, as a result of the
second intravenous injection of endotoxin, fibrin cannot be cleared
sufficiently rapidly and excess circulating fibrin is filtered by
glomerular capillaries which become occluded. Small vessels in other
organs also filter fibrin. Both reactions, local and generalized, are
inhibited by anticoagulants (29) .
The intrinsic pathway of coagulation has been implicated in the
disseminated intravascular coagulation (DIC) reactions described
above, since the Hageman factor (factor XII) is activated by
endotoxin (76) . Activated Hageman factor leads eventually to the
conversion of prothrombin to thrombin. Extrinsic factors are also
thought to be involved since leukocytes are needed to produce both the
local and generalized Shwartzman reactions. Monocytes release tissue
factor (TF), which initiates clotting via the extrinsic pathway (77)
The most likely sites where endotoxin acts to initiate coagulation are
summarized in Figure 6 below.
Active Hageman
Factor Factor VII
Prothrombin Release of Tissue
Factor









Figure .6. Initiation of coagulation by endotoxin
Activated Hageman factor, in addition to its effect on coagulation,
can activate plasma prekallikrein to form kallikrein, a proteolytic
enzyme which can generate bradykinin (77) . Active Hageman factor also
activates plasminogen.
Disseminated intravascular coagulation eventually leads to a depletion
of clotting factors. Moreover, fibrinolysis is also enhanced and
fibrin degredation products accumulate in the blood where they act as
anticoagulants. These factors contribute to the serious bleeding seen
in patients with meningococcaemia and other Gram-negative
infections (29178) .
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2.3.4 Metabolic effects 
2.3.4.1 Effects on lipid metabolism
Gallin and coworkers report marked increases in the serum
concentrations of triglycerides or free fatty acids or both in
patients with Gram-negative bacteraemia (79) . Studies on rhesus
monkeys show that endotoxin significantly elevated serum triglyceride
concentrations, leading to impairment of lipid disposal
mechanisms (8°) . Levin and coworkers however, report that the mean
free fatty acid level in their patients with sepsis was not
significantly elevated and the mean serum triglyceride level remained
normal, except in the case of 5 patients who had elevated levels (81) .
Wardle suggests that lipolysis is enhanced in endotoxaemia resulting
in high circulating levels of free fatty acids and often of serum
triglycerides (82) . This is due to release of adrenalin and
noradrenalin as well as an increase in adenylate cyclase activity in
fat cells (as a direct effect of lipid A). Release of ACTH, growth
hormone and cortisol also contribute to the lipolytic activity. In
addition, lipoprotein lipase activity is also depressed.
2.3.4.2 Effects on carbohydrate metabolism
In muscle, disturbances in carbohydrate metabolism caused by endotoxin
include decreased utilization of glucose and ketone bodies, with
increased catabolism of branched chain amino acids (82) . The blood
glucose and insulin levels appear to depend on the degree of
endotoxaemia (83) . When cardiac output is still high, the blood
glucose level is elevated and the plasma insulin is three times that
found in starvation. However, when cardiac output is decreased and
blood lactate is elevated a progressive hypoglycaemia results and the
plasma insulin level is as low or lower than in starvation. The
hypoglycaemia is due to depleted glycogen stores, depressed
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gluconeogenesis, both by liver and kidneys (the synthesis of the
regulatory enzyme phosphoenolpyruvate carboxykinase is suppressed) and
8684-) .increased tissue utilization of glucose 
(82,84-86).
	low insulin
level is due to adrenalin secretion which, in turn, inhibits insulin
secretion (82,83).
2.3.4.3 Effect on serum iron concentration
Hypoferraemia occurs in mice and rats after injection of small doses
(0.1 ug) of endotoxin (29) . The fall in serum iron concentration is so
reproducible that it has been suggested as a bioassay for endotoxin.
An infusion of 5 ng/kg body weight of Lipexal, a highly purified
S.typhosa endotoxin in human volunteers resulted in a significant
decrease in the concentration of serum iron (70) .
2.3.4.4 Other metabolic effects
(a) Endotoxin depresses cellular respiration as a result of impaired
mitochondrial functioning
(86,87).
(b) Endotoxin causes damage to cell surface phospholipids, for
example in the lung alveoli (82) .
(c) Endotoxin causes cholestasis (88,89)
(d) Phosporus metabolism is disturbed in Gram-negative
septicaemia (90) . In a study on 54 patients with Gram-negative
septicaemia, hypophosphataemia is reported in 69% of the cases.
2.3.5 Tumour necrosis 
Endotoxin causes haemorrhagic necrosis of tumours in guinea pigs,




Injection of sublethal doses of endotoxin to pregnant rats and mice
resulted in abortion and resorption of the foetuses (93) . Placental
haemorrhaging occurs and has been related to serotonin release.
2.4 GRAM-NEGATIVE BACTERIAL INFECTIONS IN MAN
Infections caused by Gram-negative bacteria have become increasingly
common. In a study at the University of Minnesota it was found that
the number of patients with Gram-negative bacillary bacteraemia has
increased from 4,9 per 1 000 hospital admissions in 1958 to 8,1 in
1966 (94) . Moreover, the mortality rate due to bacteraemia increased
from 37% to 57% in the same period. A study in Boston revealed an
incidence of 10,7 episodes of Gram-negative bacillary bacteraemia per
1 000 hospital admissions between 1967 and 1969 (95) . The annual
frequency, in the United States, of Gram-negative bacteraemia has been
estimated at approximately 1 per 100 hospital patients, with fatality
rates of 30-50% (5) .
Escherichia coli is the species most frequently isolated from blood
cultures (94 / 95) . The Minnesota study points to an increase with time
in bacterial isolates of the klebsiella-enterobacter-serratia
group
(94)
. In 1958, only 8 isolates of this group were recorded
compared to 25 in 1966. Bacteraemia due to pseudomonas species has
shown a less marked increase in yearly isolation.
A similar trend emerged from the Boston study (95) . Table 2 identifies
the specific Gram-negative organisms responsible for the bacteraemia.
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Table 2 
A study of 149 consecutive clinical episodes of bacillaemia due to
Gram-negative or apisms, during 1967-1969 at the Peter Bent Brigham
Hospital, Boston ').
Gram-negative Species No. of Isolates Percentage








Providence 1 < 1
Unclassified 2 1
Table 3 shows the incidence of the more common Gram-negative bacterial
species in blood cultures of patients at the King Edward VIII Hospital
in Durban for 1980 and 1981.
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Table 3 
Common Gram-negative isolates from the blood cultures of patients
at the King Edward VIII Hospital in Durban, 1980 and 1981.
Gram-negative species 1980 1981
isolated from blood
cultures % Total % Total
Gram-negative Gram-negative
No. isolates No. isolates
Salmonella typhi 429 26 245 18
Klebsiella 285 17 318 23
Escherichia coli 265 16 315 23
Enterobacter (including 195 12 63 5
Serratia)
Salmonella sp. 127 8 92 7
Pseudomonas 82 5 102 7
Figures for 1980 were obtained from the Department of Microbiology at
the King Edward VIII Hospital (Y.M.Coovadia, pers.camm.*)
Figures for 1981 were compiled from the data of the Antibiotic Study
Group of South Africa (96) .
The increased and widespread use of antibiotics has been implicated as
a major contributing factor to the more frequent apprearance of
Gram-negative bacteraemia (97) . Wolff and Bennett comment that the
"use of antimicrobial agents tends to promote emergence of
gram-negative organisms with intrinsic or acquired resistance to these
agents, and predisposes the patient to colonization with resistant
exogenous gram-negative organisms" (99) . Serratia marcescens, for
example, is resistant to all antibiotics except gentamicin and has
become a serious problem in hospital-acquired infections (97) .
*Dr. Y.M. Coovadia, Department of Microbiology, University of Natal,
Durban.
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A study of neonatal sepsis at the Yale-New Haven Hospital in the
United States, revealed that cases due to Pseudomonas aeruginosa first
appeared after 1943 and those due to Klebsiella-Enterobacter did not
occur until after 1957 (97) . Sulfonamides had become widely used by
1943 and by 1951 penicillin, streptomycin as well as the so-called
"broad-spectrum" antibiotics (e.g. chlorotetracycline and
chloramphenicol) were extensively used.
Other factors also contribute to the increased number of infections
reported. Therapeutic agents such as cytotoxic immunosuppressive
drugs and adrenocorticosteroids lower host defences and thus enhance
susceptibility to infections. Septicaemia is said to be the major
cause of death in patients with cancer (4) . In a study of septicaemia
in children with cancer the most frequently isolated Gram-negative
organisms were reported to be E.coli, Klebsiella pneumoniae and
Pseudomonas aeruginosa.
Patient resistance to infection is also lowered by neutropaenia and
the immune disorders of leukaemia and lymphoma (3) . It has been
claimed that, despite the best available treatment, many leukaemic
patients die from pseudomonas and klebsiella septicaemia. Braude
suggests that failure of therapy in Gram-negative bacteraemia is due
to multiple drug resistance, as well as to the toxicity of the
lipopolysaccharide (3) .
Patients with neoplasia, cirrhosis, diabetes mellitus and other
conditions are surviving longer than in the past (94,98) . Such
patients, whose defence mechanisms are often compromised, are more
susceptible to bacterial infections. Gram-negative bacteraemia is
thought to be more prevalent in older persons and the greater
proportion of elderly persons among hospitalized patients is yet
another factor contributing to the increase in Gram-negative bacterial
infections(98).
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Finally, there is a marked increase in the number of surgical
procedures being carried out (94) . These include, for example,
manipulations of the genitourinary and gastrointestinal tracts, which
are, in turn, important sites for the entry of bacteria into the
circulation. Similarly, the more frequent use of devices such as
intravenous and bladder catheters and inhalation equipment is also
implicated in the spread of bacterial infections (98) .
2.5 CONVENTIONAL THERAPY FOR ENDOTOXAEMIA
2.5.1 Introduction
Endotoxaemia can now be identified using the Limulus amebocyte lysate
technique (81) . If the endotoxaemia is derived from a septic focus,
this must be removed (99) . In the absence of a septic focus, the
intestines have been shown to be a major source of endotoxin. In such
cases there may be a-failure of the reticuloendothelial system in the
liver to clear and destroy endotoxin entering the circulation.
Fine and colleagues suggest that "treatment should be primarily
concerned with eliminating the endotoxaemia and preserving what is
left of the antibacterial potential in the R.E.S." (99) . They consider
that "the main thrust of therapy will be wrongly directed if it is
aimed, for example, at the respiratory disability which is secondary
to an endotoxaemia".
Nevertheless, the basic principles guiding therapy in septic shock are
volume expansion, correction of metabolic abnormalities, for example
restoration of normal blood pH, and correction of hypoxia by providing
respiratory assistance.
Plasma expanders are used in an attempt to restore intravascular
volume (1°°) . The best choice of fluid type remains controversial. If
the haematocrit is low, whole blood or packed red cells are used. For
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other patients a choice is made between colloidal (e.g. low molecular
weight dextran, albumin) and crystalloid solutions. However, patients
in endotoxin shock may not respond well to volume replacement. In
endotoxaemia, microcirculation abnormalities result in "leaky"
capillaries so that administered fluid is transferred into the
interstitial fluid resulting in oedema. Seventy-five percent of the
administered electrolyte solutions leave the vascular space within
minutes and may lead to congestive heart failure (1°°) . Fine and
coworkers using a haemorrhagic shock model, report that "large volume
intravenous infusion therapy, using either physiologic saline solution
alone or albumin in physiologic saline solution, is harmful by
producing marked edema of tissues, pulmonary edema, serous effusions,
venous distension and widespread hemorrhage from small vessels" (101) .
Vasoconstrictors have been used in an attempt to reverse the
hypotension caused by endotoxin
(102)
 . However, these agents improve
cardiac output by diverting blood from the vascular beds of the
kidney, gut, liver and extremities. The generally accepted principle
that intense vasoconstriction is a self-defeating mechanism has led to
investigation of anti-adrenergic therapy in experimental shock. Drugs
such as phenoxybenzamine have been found to be effective when used
prophylactically but are useful in preventing death from endotoxic
shock in experimental animals only if administered within thirty
minutes after onset of the shock state (103) .
The use of various drugs and antibiotics in the treatment of septic
shock is outlined below. Other treatments, such as extracorporeal
haemoperfusion, are also examined.
2.5.2 Steroids 
The use of large but not small doses of corticosteroids for treatment
of septic shock and endotoxaemia have been shown to be beneficial both
(104-107) .in animal models and clinically Corticosteroids have been
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shown to increase survival time particularly when given
prophylactically (1°5) .
Endotoxin-induced hypoglycaemia and lacticacidaemia were alleviated by
administration of glucocorticoids
(108).
Glucocorticoids have been shown to prevent the disseminated
intravascular coagulation induced by endotoxin (109) . In rats,
glucocorticoids interfere with the in vivo mechanism of activation of
Hageman factor as well as with the availability of platelet
procoagulant activity. As a consequence, vasoactive substances such
as serotonin, and the kinins are not released.
Steroids are able to stabilize lysosomal membranes and have been shown
to prevent the release of hydrolytic enzymes into the circulation,
during shock
(110)
. O'Flaherty and colleagues suggest that certain
complement-inhibiting effects of corticosteroids, particularly their
ability to inhibit formation of a neutropaenia-inducing substance
(NIS), may underlie their protective role in endotoxaemia
(111).
The ability of corticosteroids to increase survival time in septic
shock may be related to protection against a haemoconcentration (105) .
This could be the result of partial protection against the increased
vascular permeability seen in septic shock.
Fine and colleagues report that corticosteroid treatment prevents the
endotoxaemia of intestinal origin which results when rabbits are
subjected to immersion burns (104).






Prostaglandins have been reported to be released following LPS
administration in man and in experimental animals (42) . Drugs which
block prostaglandin synthesis or release, such as indomethacin have
been shown to influence the course of the shock state.
Parratt and Sturgess have demonstrated that in cats, indomethacin
administration prior to E.coli endotoxin injection prevented the
initial pulmonary vasoconstriction and alleviated some of the
characteristic features of delayed endotoxic shock
(112)
 . However,
when they studied the effects of indomethacin administration 30
minutes after injection of E.coli endotoxin, the cats all exhibited
the characteristic features of the shock phase, i.e. hypotension,
hypoglycaemia, reduction in cardiac output and a marked metabolic
acidosis (113) .
Multiple doses of indomethacin were found to protect dogs against
E.coli endotoxin-induced shock
(114). 
Plasma volume losses of
indomethacin treated animals were substantially less than in untreated
animals. In this study, nicotinic acid was found to have a similar
effect to that of indomethacin. It is postulated that nicotinic acid
prevents the release of fatty acid precursors of prostaglandins and
consequently reduces formation of prostaglandins. Indomethacin has
also been shown to improve the survival of baboons in endotoxic
shock (115) .
Fletcher and Ramwell have compared the effectiveness of indomethacin
and aspirin treatment of endotoxaemia in dogs and find that although
all the dogs in both treated groups survive, only those treated with
indomethacin show improved haemodynamic status after endotoxin
injection (16) . Both indomethacin and aspirin were equally effective
inhibitors of the increase in circulating prostaglandin evoked by
29
endotoxin. It is suggested that the early haemodynamic events in the
dog may not necessarily be related to survival since aspirin treatment
did not alter these events and that the primary factor in survival in
the dog may not be inhibition of prostaglandin synthesis but may be
related to other actions of aspirin and indomethacin.
In contrast to the studies described above, it is noteworthy that
there is also some evidence to show that administration of components
of the arachidonic acid-prostaglandin system will improve the shock
state (117) . There are reports of improvement in blood pressure and
cardiac output during endotoxin-induced shock with PGE 1 and PGA 1
infusions; however, there is no improvement in survival.
Fletcher and Ramwell have investigated the effects of prostacyclin
117,118). PGI
2(PGI 2 ) treatment in a canine endotoxin model ( is a
major metabolite of arachidonic acid and is synthesized in vascular
endothelial cells. It is a potent inhibitor of platelet aggregation
and a vasodilator. Survival was increased to 83% over the control
level of 42%. The authors suggest that the synthesis and release of
PGI 2 may be inhibited during shock, thereby allowing the vascular
endothelium-platelet interaction to be altered, in which case
platelets and other formed elements would adhere to vessel walls and
impede microcirculatory flow.
Although there may be some therapeutic benefit in the administration
of components of the arachidonic acid-prostaglandin system, it is more
likely that drugs used to inhibit the prostaglandin synthesis and/or
release are more effective in improving survival
2.5.4 Lidocaine
Lidocaine in therapeutic doses has been shown to improve the survival
of baboons in endotoxic shock (115) . The mechanism by which lidocaine
improves survival is not known, however it is known that lidocaine
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stabilizes cell membranes and decreases membrane permeability. It is
also known to decrease mesenteric vasoconstriction during endotoxin
shock.
2.5.5 Dopamine
Dopamine is known to cause vasodilatation in the renal vascular
x(119). Infusion of dopamine in baboons receiving endotoxin
improved the cardiovascular status of the animals. Dopamine infusion
improved the blood flow to the kidney which was attenuated by
endotoxin.
2.5.6 Naloxone
Endogenous opiates are thought to be released due to the action of
endotoxins and may contribute to reduction of blood pressure.
Naloxone, a specific opiate-antagonist, was found to temporarily
reverse endotoxin-induced hypotension in experimental animals
(61,62).
2.5.7 Proteinase inhibitors 
Endotoxins damage the membranes of leucocytes and other cells causing
certain cell components including lysosomal enzymes to be released.
The action of these enzymes include the non-specific proteolysis of
blood proteins (52) .
The proteolytic activity of elastase, cathepsin G and other
proteinases from polymorphonuclear leucocytes is inhibited in vivo by
complex formation with endogenous inhibitors. During septic shock,
consumption of proteinase inhibitors is evident and the endogenous
inhibitor system of the organism may be overstressed due to a massive
release of lysosomal proteinases.
The elastase-cathepsin G inhibitor from soya beans and a broad
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spectrum proteinase inhibitor aprotinin have been used in the
treatment of endotoxaemia in dogs. With the simultaneous
administration of endotoxin and inhibitor the consumption of plasma
factors corresponded to that of control animals. The degradation of
Factor XIII, a sensitive substrate for granulocytic elastase, was
almost completely prevented by elastase inhibitor.
While animal studies appeared promising, no successful clinical trials
on humans have been reported.
2.5.8 Antibiotics 
The value of antibiotics in the treatment of Gram-negative sepsis is
limited. Many bacteria have become resistant to various antibiotics
and their sensitivity to a specific drug can no longer be simply
deduced from species identification
(120) . In vitro measurement of
drug susceptibility is required to measure the ability of a drug to
inhibit growth of a pathogenic organism.
There has, however, been considerable interest in the polymyxins.
Polymyxin B, a cyclic polypeptide, has been shown to have unique
antiendotoxin properties, protecting against injury by
lipopolysaccharide by disrupting its structure as shown by electron
microscopy
(121) 
Polymyxin B has been shown to neutralize endotoxin
effects in animals given purified endotoxin, dead endotoxin-containing
organisms and in Gram-negative septicaemic animals
(122). 
The
antiendotoxin effect of the antibiotic appears to be separate from its
antimicrobial effects.
Although the exact mechanism of the protective effect of polymyxin B
against endotoxin is unknown there appears to be interaction between
the cationic antibiotic and the negatively charged KDO - lipid A
moiety of the endotoxin (123) . In the intact bacterial cell, this
interaction results in complete loss of structural integrity of the
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outer membrane.
Bannatyne and coworkers have found that polymyxin B diminishes the
endotoxin mediated release of human blood neutrophil lysosomal enzymes
and suggest that, in addition to having endotoxin inactivating
properties, polymyxin B may also act by blocking access of endotoxin
to surface receptor sites on the neutrophil
(124).
Polymyxin B has been used clinically in the treatment of endotoxaemia,
for example, in patients with cirrhosis
(125,126). 
The usefulness of
polymyxin B is however limited since it is nephro-toxic (127) . The low
doses administered do not give blood levels adequate for severe
systemic infections
(120).
Table 4 below lists common Gram-negative organisms and some of the
antibiotics used in their treatment
(120)
 . Some of these antibiotics
are highly toxic, for example, gentamicin and kanamycin, while others
like carbenicillin, a semi-synthetic penicillin, have a tendency to
produce drug resistance.
Table 4 
Common Gram-negative organisms and preferred antibiotics
(120)
Organism Drugs 
E.coli ampicillin, cephalothin, kanamycin
gentamicin
Klebsiella cephalothin, kanamycin
Enterobacter kanamycin, carbenicillin, gentamicin
P.mirabilis ampicillin, cephalothin
Indole-positive Proteus kanamycin, carbenicillin, gentamicin
Pseudomonas carbenicillin, gentamicin, polymyxin B or E.
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2.5.9 Fibronectin
Humoral opsonic factors modulate the phagocytic behaviour of the cells
of the reticuloendothelial system
(128)
 . One such opsonic factor is a
circulating protein fibronectin also called opsonic 0( 2 surface
binding glycoprotein or cold-insoluble globulin. An insoluble form of
fibronectin is also found in connective tissue, basement membranes and
on various cell surfaces. Saba has suggested that "multiple organ
failure occurring in patients who develop severe sepsis after trauma,
burn or operation may be, in part, related to coexistent phagocytic
dysfunction mediated by opsonic fibronectin deficiency".  Plasma
fibronection deficiency and associated opsonic deficiency in septic
shock patients can be reversed by intravenous infusion of fresh plasma
cryoprecipitate which is rich in fibronectin. However, the
therapeutic value of fibronectin therapy is in dispute.
2.5.10 Glucose therapy
Sepsis due to Gram-negative organisms results in hypoglycaemia due to
impaired gluconeogenesis, depleted glycogen stores and an increased
rate of glucose oxidation
(82,84-86).
Glucose infusions have been shown to have a curative effect in
Gram-negative septicaemia. Dogs received an infusion of E.coli and
those with elevated blood glucose levels showed a 1000-fold decrease
in circulating bacteria within 2 hours when compared with control
animals (129) . Hinshaw and coworkers have shown that in experimental
endotoxic shock in dogs exogenously administered glucose improves
certain cardiovascular and metabolic parameters and prevents
death (13()) .
2.5.11 Extracorporeal haemoperfusion
The conventional treatments used for endotoxin shock do not usually
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have a detoxifying effect on the circulating levels of endotoxin. It
has therefore been suggested that some method of diluting or removing
the circulating endotoxin be employed.
The use of haemodialysis to remove endotoxin from the circulation is
precluded since the molecular size of endotoxin is too large to be
dialyzed by currently available haemodialysis units (131) .
Nakamura and coworkers injected rabbits with E.coli endotoxin and two
hours later treated them with a total body washout (TBW) i.e. total
removal of endotoxin-contaminated blood followed by its replacement
with fresh blood (131) . Although this did improve survival in rabbits,
the drastic procedure is unlikely to be used clinically as a general
technique. Total body washout has been employed in a few human cases;
Klebanoff and coworkers report the use of the technique in treatment
of stage IV hepatic coma
(132)
Endotoxin binds nonspecifically to charcoal and it has been removed
from human blood by perfusing the blood through an extracorporeal
charcoal filter (133) . Sterile columns of purified activated charcoal
which have been coated with an acrylic hydrogel are used for this
purpose. The gel reduces adsorption of platelets which would
otherwise lead to severe thrombocytopaenia. Gazzard and coworkers
treated 22 patients in grade IV coma from fulminant hepatic failure
with charcoal haemoperfusion and found that the procedure was well
tolerated with 11 of the patients regaining consciousness and ten
leaving hospital. However, in a subsequent study, of 34 patients




Sane of the treatments used in an attempt to lower the high mortality
rate from Gram-negative bacteraemia have been described. However,
despite the use of powerful antibiotics, high doses of
adrenocorticosteroids, modern life-support systems and sophisticated
monitoring devices, the incidence of bacteraemia continues to
increase, with sustained high mortality rates (6) . An important new
approach to therapy for Gram-negative bacteraemia has been the
introduction of human antibodies directed against endotoxins. The
studies which have led to the development of these antiendotoxin
antibodies are summarized in section 2.6.7 (Antiendotoxin antibodies).
Clinical trials, which have shown the effectiveness of immunotherapy
for Gram-negative bacteraemia, are also discussed.
2.6 HOST DEFENCE SYSTEMS AGAINST ENDOTOXINS
2.6.1 Introduction
Normal host defence against microbial invaders depends on an intact
humoral and cellular system of inflammation and specific immunity. It
has been aptly said that "these (endotoxins) molecules are read by our
tissues as the very worst of bad news. When we sense
lipopolysaccharide, we are likely to turn on every defense at our
disposal" (135) . The major mechanism for killing bacteria is the
action of phagocytic cells. However, humoral factors enable these
cells to recognize, migrate towards and, ultimately, kill the
invaders. Humoral factors include antibacterial immunoglobulins plus
the proteins which comprise the complement system.
Sane of the principal effects of endotoxins on host cellular mediation
systems are outlined below. The effects of endotoxin on the
complement system and on antibody formation are then discussed.
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2.6.2 Polymorphonuclear leukocytes - granulocytes 
Endotoxin-induced leukocytosis (i.e. increase in the number of
leukocytes) occurs in humans at subpyrogenic doses (i.e. <109 g/ml)
and is secondary to the release of granulocytes from the granulocyte
reserves
(70,136)
The neutropaenia (reduction in neutrophil
concentration in the blood) common to other animals is however not
always seen in man. Higher doses of endotoxin are required for
neutropaenia than for leukocytosis (70) . Neutropaenia results from the
sequestration of neutrophils by capillaries of the lung and other
organs
(136)
. Corrigan and coworkers suggest that the lipid A portion
of endotoxin is critical in the induction of neutropaenia following
endotoxin injection (137) .
(The role of complement proteins in the mediation of the phagocytic
activity of granulocytes is discussed in the section on complement,
2.6.6).
2.6.3 Mononuclear phagocytes - monocytes and macrophages 
The blood monocytes and tissue macrophages are important in host
defence against microbial invaders not only as a result of their
phagocytic properties but also because they may be stimulated to
release various substances such as prostaglandins and
collagenases (77) . These cells are particularly sensitive to the
presence of endotoxins, many responses being observed in vitro with
the addition of submicrogram quantities of endotoxin.
Endotoxins activate monocytes, enhancing their ability to phagocytose
bacteria (138) . Monocytes undergo marked changes in both shape and
cytoplasmic organization in response to endotoxin. Endotoxins also
stimulate the formation of lysosomal hydrolases by monocytes.
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Wahl and coworkers report that activation of peritoneal macrophages by
endotoxin, particularly the lipid A component, induces the cells to
produce collagenase (139) . The production of collagenase by the
endotoxin-stimulated macrophages was significantly inhibited by
indomethacin, suggesting that prostaglandins mediate this
effect (140)
Exposure to endotoxin enhances the production of plasminogen activator
(a trypsin-like serine protease) by macrophages
(141).
Endotoxins can stimulate peritoneal exudate cells to become cytolytic
for tumour cells
(142).
Exposure of murine blood monocytes, spleen cells or peritoneal exudate
cells to endotoxin results in secretion of a colony stimulating factor
(CFS) which is required for the growth of granulocytic and monocytic
cells in vitro (77) .
Purified populations of both human peripheral blood monocytes and
murine peritoneal macrophages have been shown to synthesize and
release prostaglandin E in vitro (143) . This production of
prostaglandin E by macrophages is markedly enhanced by endotoxin and
completely suppressed by indomethacin.
2.6.4 Lymphocytes 
Endotoxin stimulates proliferation of a large subpopulation (nearly
50% of spleen cells of murine strains studied) of lymphoreticular
( )cells
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 . This mitogenic effect is elicited by the lipid A
component of endotoxin and was shown to be thymus cell-independent and




Endotoxin-induced thrombocytopaenia is seen in certain experimental
animals, for example, rabbits, guinea pigs and dogs (77) . Primates,
including man, are much less susceptible to thrombocytopaenia after
endotoxin injection than are lower mammals. Only small decreases in
platelet counts are reported in studies on human volunteers receiving
two endotoxin injections (70) .
One of the mechanisms of the platelet-endotoxin interaction depends on
the presence or absence of immune adherence receptor sites on the
platelet membrane (77) . (The aggregation of blood cells in the
presence of antigen, antibody and the first four components of
complement has been termed immune adherence. Receptors mediating
immune adherence are present on platelets in non primate species, but
in primates the erythrocyte is the reactive cell (145) ). Platelets
from primates do not respond significantly to endotoxins since they
lack immune adherence receptor sites.
Platelet responses are characterized by aggregation and the release of
platelet constituents, for example, ADP, platelet factor 3, histamine
and serotonin (77) .
2.6.6 COMPLEMENT
The complement system present in plasma consists of a series of
inactive proteins which may be activated in a sequential manner
(146).
Active complement components help to bring about the destruction of
bacteria. The complement system can be activated in at least two
different ways. The so-called "classical" activation sequence
involves antibodies (IgG, IgM). These antibodies activate the first
complement component (Cl which then activates the second and fourth
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components (C2 and C4). This leads to activation of the third
component (C3). Thereafter, a terminal sequential cascade of
reactions is triggered, activating components C5 to C9.
The "alternative" pathway can be activated, without involving
antibodies, by various substances including polysaccharides such as
inulin, zymosan and endotoxin (147) . These components also trigger
activation of C3 leading to the same terminal cascade of enzymatic
reactions as in the classical pathway. The two pathways are
summarized below in Figure 7.
CLASSICAL PATHWAY ALTERNATIVE (PROPERDIN) PATHWAY









Figure 7.An abbreviated scheme of the two pathways of complement activation
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Membranes are the primary target of complement
(146)
. They may be
irreversibly damaged, sustaining distinct ultrastructural lesions. In
general, Gram-negative organisms are susceptible to the action of
complement, while Gram-positive species are resistant. The
differential susceptibility has been linked to differences in
phos pholipid content and thickness of the cell wall.
An important role of the complement system is to potentiate the
capability of granulocytes to kill bacteria
(148)
 . C3b, a cleavage
product that results from activation of C3 is able to opsonize
bacteria i.e. alter bacteria so that they are more readily and
efficiently engulfed by phagocytes. Granulocytes and monocytes have
receptors for this and other complement components and so readily
attach to and ultimately phagocytose complement coated bacteria.
Granulocyte migration to the sites of infection is also directed by
complement components. Thus, the complement system not only prepares
bacteria for phagocytosis by coating them with C3b but it also
produces substances that attract phagocytic cells to the bacteria.
Individuals who are genetically deficient in various complement
components suffer chronically from infections (149) .
Several of the in vitro biological activities attributed to components
of complement or products of their cleavage are significant in the
pathophysiology of the endotoxin reaction (150) . Some of these
activities are summarized in table 5.
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Table 5 
Biological activities produced in vitro as a conswpence
of interactions between endotoxin and complement "-'°).
Biological activity Co element com • •nents involved
Anaphylatoxin C3, C5
Contraction of smooth muscle
Increased capillary permeability
Release of histamine and heparin C3, C5
from mast cells
Adherence and degranulation of platelets C3




Experiments of Spink and Vick suggest that complement components may
be involved in the lethal effects of endotoxins in dogs (151) . Dogs
were protected against the lethal effects of endotoxin by transfusions
of blood, in which an "essential serum factors (possibly complement
components) had been depleted by heating plasma at 56 °C for 30
minutes, prior to administration of endotoxin.
The action of complement is not always beneficial 
(77,149).
 The
reactions mediated by the system are not always contained and
modulated. In many cases of Gram-negative bacteraemia, there appears
to be an overactivation of the complement system. It is suggested
that high concentrations of bacteria in the circulation provide a
continuous stimulus to activation and amplification of complement
proteins. This could help explain why there is often a depletion of
complement in the serum of bacteraemic patients. As a result, the
inflammatory response can become exaggerated, producing increased
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vascular permeability, leakage of blood into the interstitial space
and release of lysosomes from white cells. Thus in many cases, the
host response to the Gram-negative organism, rather than the organism
itself, poses the ultimate threat to host tissues.
There has been considerable interest in the effect of endotoxin on
complement components. The results of some of the in vivo studies are
summarized below.
Landy and Pillemer report that injection of endotoxin into mice
induced increased levels of circulating properdin (a major protein
component of the alternative pathway)
(152,153)
 . The properdin titre
was elevated to levels two to three times the normal. The rise in
properdin levels is correlated to an increase in resistance to certain
bacterial infections. Following infection with Gram-negative
organisms, in control animals, the properdin titres progressively
declined and the animals died, while in mice pretreated with
endotoxin, properdin levels were maintained in the normal range or
increased.
In contrast Hook and coworkers report a drop in properdin levels
following injection of S.typhosa endotoxin into mice (154) . Gilbert
and Braude report that injection into rabbits of a lethal dose of
endotoxin produced a rapid and sustained fall in complement levels,
however, doses below LD 50 caused only sporadic alterations of
complement titres (155) . In a similar study it was found that serum
complement activity declined even after injection of adjuvant amounts
of endotoxin into rabbits (156) .
McCabe has studied alterations in complement levels in patients with
bacteraemia due to Gram-negative organisms (157) . In patients with
uncomplicated bacteraemia the mean C3 levels were not found to differ
from values in controls, however, a significant reduction in C3 levels
were observed in patients with shock and in those who died. Fearon
43
and coworkers provide evidence of activation of the alternative,
properdin pathway and the terminal complement sequence in patients
with bacteraemia resulting in shock (158) .
On the other hand, a recent study reveals no significant differences
in complement values between patients with non-septic shock and
healthy individuals (159) . Gram-positive septic shock showed a pastern
of complement activation similar to that of Gram-negative septic shock
and was characterized by a fall in whole serum complement, C3 and C4,
indicating classical pathway activation.
The role of endotoxin-initiated activation of complement on endotoxin
activities in vivo, has also been examined. It has been suggested
that C3 may cause some of the pathological lesions induced by
endotoxins
(160)
. Anti-complement serum (which is directed mainly
against the third component) suppressed the appearance of haemorrhage
in guinea pigs. Consistent with these results are those of Fong and
Good who depleted rabbits of C3 and the terminal complement components
and then induced localized and generalized Shwartzman reactions
(161)
A cobra venom anticomplementary factor was used to consume C3 and
terminal components. Only one of the fifteen complement-depleted
rabbits developed either the local or generalized Shwartzman reaction
while most of the control animals developed lesions.
In contrast, other workers using the same experimental system, report
completely opposite results. Bergstein and Michael were unable to
prevent the development of Shwartzman reaction lesions by prior
depletion of C3 and terminal components
(162)
. The sixth component of
complement as well as components C7-9 were also not found to be
essential to the initiation of intravascular coagulation by
endotoxin (163) . Similarly, prior depletion of complement components




Brown and Latchmann, however, show that prior C3-9 depletion appears
to be protective and correlates well with absence of mortality, normal
platelet survival and failure to activate platelet factor 3
(pF3) (165). Similarly, injection of endotoxin into rabbits
genetically deficient in C6 resulted in a high death rate, whereas
rabbits with a partial deficiency of C6 as well as rabbits with normal
levels of C6 survived 
(166).
 Thus, a critical role for C6 is suggested
in the protection of hosts against the lethal effects of endotoxins.
In an attempt to reconcile some of these conflicting results Morrison
and Ulevitch suggest that "differences in endotoxins from different
species and from the same organism prepared by different procedures,
as well as inherent differences in these various endotoxins to
activate the various complement pathways, will contribute to their
capacity to affect the complement system in vivo" (77) . They conclude
that "the interaction of complement with bacterial endotoxins in vivo 
does, at least in part, contribute to the overall host response to
endotoxin".
Endotoxins are thought to activate both the classic and the
alternative complement pathways. Endotoxin was injected into normal
guinea pigs and into guinea pigs congenitally deficient in the fourth
component of complement (C4) (167) . The C4 deficient guinea pigs are
known to have a complete block in the activation of the classical
complement pathway, but with the alternative pathway intact. In both
sets of guinea pigs there were significant drops in the levels of C3-9
after endotoxin injection.
It appears that in the classical mechanism of complement activation by
endotoxin, the antiendotoxin antibody-endotoxin complex activates C3.
In addition, lipid A binds directly to Cl leading to a "classic"
pathway which is not antibody dependent (77) . In the alternate pathway
antibody is not involved at all.
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2.6.7 Antiendotoxin antibodies 
Investigators in the 1940's established that increased resistance to
endotoxin toxicity could be generated by vaccination of animals or
individuals with endotoxin or killed Gram-negative bacteria.
Favorite and Morgan found that in humans, a purified typhoid pyrogen
induced a fever of from 103 to 105 °F when administered intravenously
in doses of from 0,001 to 0,002 mg. (7) . However, in order to obtain
similar results with subsequent injections, the amount of pyrogen had
to be increased by three- to fivefold.
Rabbits are shown to develop tolerance to the pyrogenic action of
endotoxins from S.typhosa, S.schottmuelleri or Sh.dysenteriae
following repeated intravenous injections (8) . Animals that have been
injected with any of these three antigens showed a diminished febrile
response following injection of either of the two heterologous
antigens. Morgan believed this acquired resistance to endotoxin to be
independent of antibody levels in the circulation. A similar view was
held by Beeson who failed to accomplish the passive transfer of the
tolerance
(168)
. Sera from rabbits who had been injected with a
S.typhosa vaccine were pooled and administered intravenously to
rabbits in doses of 10 ml prior to the animals being given the typhoid
vaccine. Control animals received normal rabbit serum. The febrile
response of all the rabbits, experimental and control, fell within the
range of ordinary responses and there was no appreciable difference in
the fevers in the two groups.
On the basis of other studies, Beeson suggested that tolerance to
pyrogens develops as a result of a change in the functional capacity
of the reticulo-endothelial system whereby the ability to remove
bacterial toxins from the blood is enhanced (169) .
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In 1959, Freedman reported that the passive transfer of serum from
endotoxin-tolerant rabbits protected mice against homologous and
heterologous endotoxins (9) . The "tolerant" serum lost its activity on
heating. Freedman does not however attribute the protective effect to
the antibody content of the serum. He found that the serum of
endotoxin-tolerant rabbits contained low or no antibody titres to the
endotoxins and suggests that "low antibody titers to endotoxin would
be expected from the weak antigenicity of lipopolysaccharides" (9) .
Abernathy and Spink found that sera from patients with brucellosis
contained "precipitins" for brucella endotoxin and conferred passive
protection against the lethality of brucella endotoxin for mice (10) .
The sera from 9/19 patients with brucellosis protected mice against
the lethality of brucella endotoxin. None of the control sera
protected mice. It was also found that injections of brucella
endotoxin into humans caused the formation of serum "precipitins" for
the endotoxin.
Ritts and coworkers found that tolerance to a specific endotoxin was
the result of a specific rise in antibody with only a
slight-to-moderate increase in heterologous antibody (170) . They
showed that "tolerant" serum, containing high concentration of
specific antibody, when transferred to normal mice gave absolute
protection against a lethal combination of bacteria and endotoxin.
When this serum was heated for 1 hour at 56 00 and transferred to
normal mice, the mortality rose to 83%.
By 1964 Landy and Weidanz concluded that "it should be evident that in
experiments in animals and man which involve parenteral injection of
endotoxin, intravascular antigen-antibody reactions are
produced" (171) .
In order to investigate the immune responses to infection, Braude and
his coworkers injected E.coli 0:113 into the knees of rabbits and
established a severe arthritis which was accompanied by fever lasting
























two weeks (172) . Endotoxin but not bacteria was found in the blood of
these febrile animals. Antibody titres against E.coli endotoxin
appeared at their maximum level on about the seventh day after
infection with E.coli. From this time on there was a decline in the
fever peaks, even though endotoxin was shown to persist in the
infected knees long after. It is suggested that antibodies might
neutralize the pyrogenic properties of endotoxin persisting in the
knee. To examine this further, rabbit antiserum with a high titre of
antibodies was prepared by repeated intravenous injections of
endotoxin from E.coli 0:113. Immune serum was injected with 1,0 ,pg of
endotoxin into rabbits and was found to markedly inhibit the pyrogenic
response by reducing or abolishing the second peak of the fever curves
observed with endotoxin and normal serum. This is illustrated in
Figure 8 below.
Figure 8. Effects of antibody on pyrygeNc response to
Escherichia coli endotoxin" 72) .
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E.coli infection was shown to stimulate the production of protective
antibodies against endotoxin (173) . Subcutaneous injection of
antiserum from rabbits immunized with boiled cells of E.coli 0:113 was
able to reduce the lethality of E.coli 0:113 endotoxin in mice by
50-80%. Antiserum to an E.coli 0:113 mutant whose endotoxin was
deficient in side chains was also found to be just as protective.
Significantly, antiserum against S.abortus equi gave just as much
protection against E.coli endotoxin as homologous antiserum. From
these observations it was suggested that antibody to the type-specific
oligosaccharide "0" side chains of endotoxin, was not necessary for
protection. These results were confirmed by a later, extensive study
in which it was found that protection was not limited to the
homologous antisera but that antisera against endotoxins from
unrelated bacterial species also showed a wide range
cross-protection (174) .
Rabbit antiserum, with high titres of antiendotoxin antibodies was
shown to be effective in preventing the local Shwartzman reaction to
homologous endotoxin when compared to nonimmune rabbit serum (175)
Antiserum to E.coli 0:111 endotoxin reduced the frequency of
Shwartzman reactions from 98% to 9,6% in animals given E.coli 0:111
endotoxin. Antiserum to S.typhimurium endotoxin reduced the frequency
of Shwartzman reactions from 100% to 30,3% in animals given
S.typhimurium endotoxin. S.marcescens antiserum cut in half the
frequency of the reaction in rabbits given S.marcescens endotoxin.
S.typhimurium antisera reduced the frequency of E.coli 0:111 induced
local Shwartzman reactions in rabbits from 98% to 50%. When the
experiment was reversed, E.coli 0:111 antiserum did not reduce
S.typhimurium induced local Shwartzman reactions. However, antiserum
to a epimerase-deficient rough mutant, J5, of E.coli 0:111 did prevent
S.typhimurium from producing the local Shwartzman reaction. The
endotoxin of the J5 mutant is deficient in "0" antigenic units. It
was suggested that antiserum prevents the Shwartzman reaction by
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acting against a toxic antigen common to endotoxins from unrelated
bacterial genera. Loss of the "0" antigenic units was thought to
enhance the production of protective antisera, i.e. core antigens,
shared in common by E.coli and S.typhimurium are "unmasked" when "0"
specific side chains are not synthesized (175) .
The ability of antiserum to prevent the local Shwartzman reaction
suggested that such serum might also prevent the generalized
Shwartzman reaction with its attendant disseminated intravascular
coagulation. Rabbit antiserum was shown to prevent intravascular
coagulation if given before the first endotoxin injection and to
arrest the reaction if given immediately before the second endotoxin
injection (176) . Intravascular coagulation was also prevented by
antiserum to both heterologous bacteria and side-chain - deficient
mutants. The protection by antiserum was found to be independent of
complement.
The protective power of the antisera was now investigated in a lethal
bacteraemia model. Most of the studies so far described involve the
direct intravenous injection of bacteria or their endotoxins into
experimental animals. A model was now developed in order to reproduce
in animals the form of bacteraemic shock that sometimes follows
instrumentation (177) . Bacteraemic shock in man sometimes develops
after pelvic instrumentation and invasion of the bloodstream by E.coli 
and other Gram-negative organism normally resident in the colon.
Their method is based on the fact that most of their laboratory
rabbits had low concentrations of coliform bacteria in their bowel.
Enteric Gram-negative organisms can therefore be introduced
selectively into the intestinal tract. Bacteria were fed to
coliform-free rabbits in their drinking water and their faeces soon
became heavily populated with the organisms. Nitrogen mustard was
then given intravenously to produce granulocytopaenia, which is a
common feature of human bacteraemia. A temperature probe was inserted
into the rectum to mimic pelvic instrumentation of patients as well as
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to detect development of fever. The bacilli invaded the pelvic veins;
the animals developed high fever, vascular collapse and died. In
summary, the model resembles lethal bacteraemia in humans with respect
to the endogenous source of the bacteraemia, the immune disturbances
and the prominence of vascular collapse.
Ziegler and coworkers used the above technique to produce bacteraemia
in rabbits, with either Klebsiella pneumoniae, E.coli 017 or E.coli 
04 (178) . The animals were treated with antiserum produced by
immunization of rabbits with the UDP-galactose-deficient mutant, J5 of
E.coli 0:111. When normal serum was given intravenously at the onset
of bacteraemia with any of the three organisms, only 3% to 6% of the
animals survived. When animals received antiserum to the J5 mutant,
the survival rates were 33,3% from E.coli 04, 40% from Klebsiella, and
69,2% from E.coli 017 (a multiple antibiotic-resistant strain).
Antiserum to the parent E.coli 0:111 (with the "0" antigens intact)
provided no significant protection. Thus, the J5 antiserum was shown
to give broad protection against different Gram-negative organisms.
Rabbits given the J5 antiserum also cleared labelled bacteria more
rapidly than those given normal sera.
Chedid and coworkers found that administration of high titre antiserum
prepared in a horse immunized with a rough S.typhimurium strain,
TV 119, protected mice infected with a highly virulent strain of
1K.pneumonlae
(179)
 . The protective effect of this antiserum was
removed by absorption with rough organisms but not by smooth strains
of S.typhimurium or S.typhi. Also, provided the Klebsiella were
preincubated in normal mouse serum bactericidal activity could also be
demonstrated in vitro. These authors had previously observed that
viable klebsiella organisms recovered from the liver of
endotoxin-stimulated mice and reinoculated to normal recipients were
cleared very rapidly "as if they had been modified into a rough
strain" (they had found that in contrast to the 0 antigen, rough
endotoxin is cleared very rapidly from the blood of normal mice). In
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view of these and other observations Chedid proposed that host serum
enzymes are capable of removing smooth determinants from the surface
of Gram-negative bacilli thus exposing R antigenic sites common to
many bacterial strains and species and so providing a mechanism which
enabled antibodies to rough determinants to protect against smooth
bacteria. The system was seen as a primordial defence mechanism which
phylogenetically predated the evolution of type specific immunity.
There was now considerable evidence to show that antibodies to rough
determinants might protect against infections with heterologous smooth
bacilli and McCabe suggested "that the cross protection induced by
immunization with rough bacilli might prove clinically useful"
(180) .
He studied the effect of active and passive immunization of mice with
various rough mutants of S.minnesota on experimental bacteraemia from
heterologous Gram-negative bacilli.
The rough mutants Ra 60, Rb 345, Rc 5, Pel l 7, Rd23 and Re 595 of
S.minnesota and the parent smooth strain S 218 were used in McCabe's
experiments. Figure 9 below shows the chemical structure of the
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Figure 9. Chemical structure of lipopolysaccharides derived from cell walls of





3 and Re 595
180 ) . (GNAc, N-acetylglucosamine;
Glu, glucose; Gal, galactose; Hep-P, heptose phosphate;
KDO, 2 keto-3-deoxyoctonate).
Active and passive immunization of mice with the Ra, Rb, Rc and Rd,
mutants of S.minnesota failed to protect against challenge with
K.pneumoniae. However, active and passive immunization with the Rd 2
and Re mutants afforded significant protection against challenge with
K.pneumoniae. Passive immunization with Re and active immunization
with Ra, Rc, Rd2 and Re provided significant protection against
challenge with E.coli 107. Immunization with Re afforded greater
protection than any of the other mutants. The protection afforded by
immunization with the Re mutant was compared to type specific
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immunization. Active immunization with the Re mutant was found to be
considerably less effective than type specific immunization,
nevertheless McCabe suggested that there are situations "where the
induction of moderate degrees of immunity against a large number of
microorganisms might be of clinical value" (180) .
Neutropaenic rabbits were protected against bacteraemia and death from
two strains of E.coli and one Enterobacter aerogines by immunization
with the Re mutant of S.minnesota
(181)
. During the course of these
studies it was found that immunization with lipid A was not
protective. The lipopolysaccharide of the Re mutant differs from
lipid A only by the presence of a ketodeoxyoctonate (KDO)
trisaccharide. It was therefore concluded from this and from in vitro
studies that KDO, not lipid A, was the important cross-reactive
antigen
(181,182).
In 1973, Ziegler, Douglas and Braude reported for the first time that
human antiserum could also confer "exceedingly potent" passive
immunity to the effect of endotoxin (12) . Twenty one men each gave a
pint of preimune blood and were later immunized with a single
injection of S.typhimurium or E.coli 0:111 heat killed cells which had
been suspended in physiologic saline. Immune serum was collected two
weeks later. lml antiserum given intravenously protected mice against
a lethal intravenous dose of homologous endotoxin. The incidence of
positive local Shwartzman reactions to homologous endotoxin was
reduced from 100 to 38% by E.coli antiserum and from 92 to 35% by
S.typhimurium antiserum. There was however no protection against 
heterologous endotoxin in either animal model. The failure of
heterologous protection with smooth antisera was explained by the
concept that "0" determinants conceal the common core of endotoxin.
In view of the fact that, antiserum from animals immunized with
"0"-deficient mutants had been shown to afford heterologous protection
against some of the adverse effects of endotoxin, it was decided to
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immunize human subjects with the "0"-deficient mutant vaccines.
Human antiserum obtained after J5 immunization was tested in a rabbit
model (183) . Pseudomonas bacteraemia was produced in experimental
animals made agranulocytic with nitrogen mustard. A broth containing
10
7 
Pseudomonas aeruginosa was instilled into the conjunctival sac.
Within 48 hours of inoculation the animals developed conjunctivitis,
facial oedema, infarction of the eyelid, and overwhelming bacteraemia,
leading to death in more than 90% of the animals. There was however a
42% survival rate among rabbits given human J5 antiserum
(intravenously, 24 hours after eye inoculation with Pseudomonas) while
only 10% of the animals which received control serum survived.
Davis and coworkers have also shown that J5 antiserum can neutralize
meningococcal endotoxin, which has been found to be biochemically
similar to enteric lipopolysaccharide
(184) . J5 antiserum also
prevented mice from lethality in experimental Haemophilus influenzae
Type b infection (185) .
McCabe and his coworkers measured antibody titres (mainly 1gM) to
0-specific antigens and to the Re determinant of rough bacilli in
patients with Gram-negative bacteraemia (5 F
186)
They found that high
titres of 0 antibody did not prevent development of bacteraemia and
were associated with only a slight decrease in the frequency of shock
and death. In contrast, both shock and death were 1/3rd as frequent
among patients with high titres of Re antibody. These observations
and previous animal studies suggested that enhancement of resistance
to enterobacteria might be accomplished by immunization with shared
cross-reactive antigens and therefore a double-blind controlled trial
using J5 antiserum was undertaken by Braude and coworkers in patients
severely ill with Gram-negative bacteraemia. Control serum was
collected from healthy, adult male volunteers who two months later
received subcutaneous injection of 5 x 10 9 heat-killed J5 E.coli in
two sites, followed by two identical injections 48 hours later (13,14) .
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The immunization is reported to have "resulted in local swelling and
tenderness in most men and in transient fever and malaise in a
minority". 14 days after immunization, immune serum was collected.
37 patients received J5 antiserum while 46 had been given control
serum. Both groups received 3 ml of serum/kg body weight. The groups
were similar in age, severity of underlying disease and incidence of
neutropaenia and they had been treated equally often with granulocytes
and high dose corticosteroids. The J5 antiserum group had more
pseudomonas bacteraemia and more profound shock before administration
of serum. Five of 37(14%) patients who received J5 antiserum died as
a direct consequence of bacteraemia compared to 12 of 46 (26%)
patients given control sera. Mortality in the J5 group was about half
that among controls. 18 patients experienced "profound shock", i.e.
their hypotension required treatment with pressors for at least 6
hours. Of these cases, only 2 of 7 controls, or 29%, recovered from
shock. In contrast, 9 of 11 (82%) patients given J5 antiserum
recovered from shock. The number of patients is small; however the
authors consider the difference to be significant (p = 0,024 by
Chi-square).
On the basis of these favourable results the trial was expanded in
order to establish the full significance of the data. A randomized
controlled trial involving 304 patients was undertaken over a seven
year period (15) . 212 patients were eventually included in the
analysis and of these 103 had received J5 antiserum and 109 had
received nonimmune serum. In the entire study the number of deaths in
bacteraemic patients was 42 of 109 (39%) in controls and 23 of 103
(22%) in recipients of J5 antiserum. J5 antiserum was particularly
effective in patients with hypotension, especially those in profound
shock, as shown in table 6.
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Table 6 
Effect of J5 antiserum on mortality from Gram-negative bacteraemia (15) .




Patients with positive blood
cultures:
38/100(38) 29/91 (24) 0.041
With hypotention 33/66 (52) 20/62 (32) 0.028
In profound shock* 26/34 (76) 17/37 (46) 0.009
Patients with negative blood
culturest
4/9 (44) 1/12 (8) 0.080+
A11 patients 42/109 (39) 23/103 (99) 0.011
With neutropenia 13/41 (32) 5/29 (17) 0.179
Without neutropenia 26/68 (43) 17/74 (23) 0.012
With hypotension 38/74 (51) 21/71 (30) 0.008
In profound shock* 30/30 (77) 18/41 (44) 0.003
*Requiring pressors for more than six hours.
tBlood was drawn after antibiotics had been given.
+With Yates' correction for small cell frequencies.
From these results Ziegler and coworkers concluded that J5 antiserum
substantially lowers mortality from Gram-negative bacteraemia. The
authors suggest that, although both the IgM and IgG fractions of J5
antiserum protect against lipopolysaccharide in the Shwartzman
reactions, it is the IgM which is more potent against infections (15) .
Most of the studies leading to the use of the J5 antiserum in the
clinical trials described above have emanated from A.I. Braude's
laboratory. There have however been numerous other studies on the
protective role of anti-LPS antibodies in Gram-negative bacteraemia
and these will now be reviewed.
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Of particular interest is the development of a polyvalent pseudomonas
vaccine of value in controlling invasive pseudomonas infection.
Infection with Pseudomonas aeruginosa is common in certain types of
patients, notably those with extensive tissue damage, particularly
following burn injury and those with cystic fibrosis or
neoplasia (187) . Early pseudomonas vaccines were monovalent but since
infection can be caused by a strain belonging to any of the 16
internationally recognized serological groups of P.aeruginosa 
multivalent vaccines were produced.
Jones and coworkers report the preparation of a polyvalent vaccine
comprised of 16 component vaccines, each a lipid-protein-carbohydrate
complex extracted from the surface of one of the 16 different
serotypes of P.aeruginosa
 (188)
 . Healthy volunteers were given three
weekly subcutaneous injections of the polyvalent vaccine
(PENT-01) (189) . Jones and coworkers report that "apart from slight or
moderate local reactions and a transient rise of temperature in some
volunteers, there were no clinical, biochemical or haematological
abnormalities in the vaccinated volunteers". Raised titres of
antibody in theserum of volunteers given 0,5 - 1.0 RHD (manufacturer's
recommended human dose) vaccine were shown against all of the 16
serotypes of Pseudomonas aeruginosa. Serum from vaccinated
individuals was shown to protect mice against challenge by
intraperitoneal injection of Pseudomonas aeruginosa P14, which killed
100% of unprotected controls. The vaccine was subsequently tested in
controlled trials at two burns units, in Birmingham (United Kingdom)
and New Delhi (India), in children and adults with burns more than 15%
full skin thickness (190) . In New Delhi where the risk of death from
pseudomonas septicaemia is high, 13 of 32 (40,6%) of the unvaccinated
adults died while only two of 20 (6,6%) of the vaccinated adults died.
In Birmingham, where pseudomonas septicaemia occurs less frequently
than in New Delhi, the number of deaths were similar in the vaccinated
and unvaccinated groups. None of the vaccinated patients in either
trial showed blood cultures containing Pseudomonas aeruginosa and
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vaccines showed raised titres of protective antibodies (both IgG and
IgM) and increased phagocytic activity against Pseudomonas.
A hyperimmune gamma globulin called pseudomonas immunoglobulin (PI)
was prepared from the plasma of healthy volunteers vaccinated with the
polyvalent vaccine,PEV-01 (16) . The efficacy of PI against pseudomonas
infection was compared with PEV-01 and combined PI/PEV-01 treatments
in a controlled clinical trial in severely burnt patients in New
Delhi. In children the mortality was lowest in those passively
immunized. All the 18 children immunized with PI survived compared
with a mortality of 21% in the unimmunized children. In adults the
mortality rate of those receiving irimunoglobulin or vaccine was 10% or
8,3%, respectively, compared with 36% in controls. Combined vaccine
and imunoglobulin treatment gave rather less protection than vaccine
alone. It is interesting to note that only small volumes of PI were
necessary to reduce the risk of pseudomonas septicaemia; the
dose-schedule for children was 0,2 ml PI by deep intramuscular
injection for 3 consecutive days, starting on the day of admission to
the hospital, while "adults" (patients > 13 years old) were given 0,5
ml instead of 0,2 ml.
Pollack and Young who measured serum antibodies to lipopolysaccharide
in 52 patients with Pseudomonas aeruginosa septicaemia also found that
high anti-lipopolysaccharide titres were associated with
survival (191) . The principal antibodies against Pseudomonas are
thought to be opsonins of the IgG and IgM hmmunoglobulin classes, but
it is unclear which, if either, is more closely associated with
protection. The antibodies are potentiated by the complement system,
activated either through the "classical" or "alternate"
pathways (192) .
An antiserum against pseudomonas endotoxin significantly protected
mice challenged with live pseudomonas cells (193) . The LD50 for
animals treated with antiserum was increased by 10 2,7 times as
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compared with the control group.
The pyrogenic activity of LPS from Yersinia enterocolitica was
neutralized by homologous antiserum (194) . The level of homologous
neutralization was markedly higher than that of heterologous
neutralization.
Small amounts of E.coli 055:B5 endotoxin injected intramuscularly into
cows induced pyrogenic tolerance and an increase in the rate at which
the serum killed a strain of E.coli (195) .
Escherichia coli is by far the main cause of human pyelonephritis.
Vaccination with formalin-treated cells of E.coli 06 protected rats
against unilateral retrograde pyelonephritis due to homologous E.coli 
serotype
(196)
. The protection was manifested by less parenchymal
destruction and shrinkage of the pyelonephritic left kidney and also
by less secondary pyelonephritis and compensatory hypertrophy in the
right kidney of vaccinated rats. Only one of the 151 rats in the
vaccinated group died while of the 162 rats in the control group, 22
died. High levels of antibody to E.coli LPS were found in the
vaccinated animals and are thought to have contributed to protection.
Mattsby-Baltzer and coworkers found that the oral immunization of rats
with a live strain of E.coli 06K13HI protected them against
experimental ascending pyelonephritis caused by the same strain (197)
Sera collected 1 week after infection from the immunized animals were
found to have increased levels of IgG anti-06 and IgM anti-K3 in
comparison with the nonimmunized controls. In urine, there was an IgG
antibody response to the 06 antigen. During a 12 month follow-up of
the infections, the serum anti-06 antibody levels remained high
throughout the entire observation period (199) . These studies thus
raise the question of whether vaccination ought to be considered for
patients predisposed to chronic bacterial pyelonephritis.
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Injection of sublethal quantities of endotoxins extracted from smooth
and rough bacterial strains have been shown to interrupt pregnancy in
mice (199) . Interruption of pregnancy is shown to be related to the
toxic lipid A moiety and not to be sero-specific polysaccharide.
Pregnant mice were treated with specific antisera obtained by
immunization of mice, horses or rabbits with heat-killed
bacteria (199) . Immune serum was found to protect mice from the
abortifacient effect of smooth or rough LPS, this activity being lost
after absorption of the antiserum with homologous bacteria.
Antibodies to lipid A protected pregnant mice challenged with lipid A
or LPS extracted from various organisms.
Research into cholera has shown that there is "correlation between the
complement-mediated serum vibriocidal activity of individuals and
their resistance to the clinic disease" (2°°) . It would therefore
suggest that the most effective vaccines would be those with a high
content of the antigens against which the vibriocidal antibodies are
directed. Since Vibrio cholerae is a Gram-negative organism the
vibriocidal antibodies are thought to be specific for LPS
determinants. Neoh and Rowley attempted to establish whether
vibriocidal antibodies are identical to anti-LPS antibodies. They
found that the antibodies which protect against cholera are mainly
those directed against the oligosaccharide determinants of LPS (2°°)
However, in addition to this, there are antibodies directed against
protein antigens present in the cell walls.
Sera from 50 patients with gonorrhoea, 30 with non-specific urethritis
and 80 blood donors were treated with mercaptoethenol and examined for
antibodies against endotoxin from Gonococci
(201) . The percentage of
sera active in a haemagglutination test was much higher in the
gonorrhoea group than in the controls. The antibodies against the
endotoxin are reported to be those of the IgG class. Rice and Kasper
found that a relatively protein free LPS preparation from Neisseria
gonorrhoea was the major antigenic constituent responsible for the
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development of bacterial antibody (IgG) in rabbits and in a patient
202)who suffered disseminated infection 
(202).
	Strains of Neisseria
gonorrhoeae are thought to vary in their susceptibility to serum
bacteriocidal activity and no specific protective role of gonococcal
bacteriocidal antibody has been identified. It is however interesting
to note the response to a polysaccharide vaccine of group A Neisseria 
meningitidis used in a field trial in Finland involving large numbers
of children during an epidemic in the 1970's
(203). 
Antibody responses
were good in children older than 18 months of age and the vaccine
resulted in a decreased incidence of the disease.
Studies have been undertaken to measure the levels of antiendotoxin
antibodies in the serum of healthy individuals as well as those
suffering from various disorders. A radioimmunoassay was used to
measure anti-E.coli antibodies in the sera of 11 healthy subjects and
72 patients with immunological or gastrointestinal disorders
(204)
IgG and IgM specific antibodies predominated quantitatively over IgA
specific antibodies. Surprisingly, in this study alone the mean
antibody concentrations were not significantly different from normal
in patients with gastrointestinal conditions such as nontropical
sprue, regional enteritis, intestinal bacterial overgrowth and chronic
liver diseases in which elevations might have been expected. Others
however reported increased frequencies of occurrence and titres of
serum agglutinating antibodies to intestinal bacteria (including some
E.coli strains) in cirrhosis and chronic hepatitis (205,206) *
Differences in sensitivities of techniques of antibody detection as
well as differences in serotypes of E.coli used may account for the
conflicting results. Brown and Lee also reported diminished
concentrations of IgG and IgA class antibodies in 5 patients with
chronic ulcerative colitis
(204)
. In a later study, sera from 30
patients with inflammatory bowel disease (16 with Crohn's disease and
14 with ulcerative colitis) were assayed for the presence of
antibodies against 159 Escherichia coli 0-antigens and compared with
sera from 16 matched control subjects (207) . The majority of patients
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with inflammatory bowel disease had agglutinating antibodies (IgG and
IgM) to a higher number of Escherichia coli 0-antigens and in higher
titres than the control group. The authors suggest that previously
only a few serotypes of E.coli were tested while in their study all
159 internationally recognized E.coli serotypes were included. Since
various serotypes of E.coli are present in different subjects unless
all the 0-antigens are tested, negative results may be reported. The
study did not however reveal any correlation between the number of
E.coli agglutinins and the site and severity of the disease or type of
therapy.
There are a number of endotoxic activities for which the lipid A
component of LPS is thought to be responsible e.g. Shwartzman
reaction, pyrogenicity and complement activation
(208)
. The question
is therefore raised as to whether anti-lipid A antibodies could be
elicited by immunization with lipid A. A lipid A vaccine was prepared
by Galanos and coworkers, and animals immunized with this vaccine
produced anti-lipid A antibodies (IgG and IgM)(209,210).
The vaccine was produced by mild acid treatment of a salmonella Re
mutant. This treatment removed KDO radicals, leaving cells with lipid
A on their surface. These cells were then coated with additional free
lipid A. Rietschel and Galanos examined the protective role of lipid
A antiserum in rabbits, using lipid A-induced fever and skin necrosis
as test systems
(211)
. It was shown that lipid A antiserum after
passive transfer, conferred significant protection against skin
necrosis and against fever providing that test animals had been
pretreated with endotoxin. In this respect, lipid A antiserum differs
from antisera specific to the polysaccharide portion of
lipopolysaccharides. Why pretreatment is necessary in lipid A
antiserum-mediated protection is not understood. Lipid A-induced
local Shwartzman reaction could also be prevented by lipid A
antiserum.
Antibodies to lipid A have been shown to be common in the sera of
healthy children and adults, suggesting that exposure to lipid A or




. Such responses may be boostered by
infections. Girls with acute cystitis, acute pyleonephritis and
asymptomatic bacteriuria showed significantly elevated levels if IgG
antibodies to lipid A as compared with children with no history of
urinary tract infection.
This review has highlighted the potential role of antibody therapy in
the treatment of Gram-negative bacteraemia. In the clinical studies
discussed, antibodies were raised by vaccination of healthy volunteers
with heat-killed Gram-negative bacteria or vaccines containing LPS.
Gaffin and coworkers have however found that approximately 7% of
plasma units in a blood bank have significant concentrations of
antiendotoxin antibodies (18) . These antibodies have been shown to
protect cats from lethal endotoxic shock secondary to haemorrhage.
Thus, by routinely screening plasma units in a blood bank and pooling
those units high in antiendotoxin titres, stocks of antibody can be
accumulated on a large scale. The last part of this literature review
(2.7) examines the measurement of antiendotoxin antibodies by
enzyme-linked immunosorbent assay (ELISA), a technique found to be
suitable for assaying large numbers of serum samples. Various
studies, by Gaffin and coworkers, on the use of their antiendotoxin
antibodies are described in Chapter 5 (5.2 and 5.3).
2.7 MEASUREMENT OF ANTIENDOTOXIN ANTIBODIES BY ENZYME-LINKED
IMMUNOSORBENT ASSAY (ELISA)
The potential of ELISA for detecting antibodies to bacteria has not
been fully exploited until recently. Nevertheless as far back as 1972
Carlsson and coworkers detected salmonella 0-antibodies in human sera
by ELISA(213 
,214)
 . When compared with the conventional tube
agglutination method (Widal reaction), passive haemagglutination and
quantitative precipitation, ELISA was shown to be more sensitive. In
addition, IgG and IgM antibodies were both detected approximately as
efficiently with ELISA. Both the passive haemagglutination method and
the Widal reaction have an important disadvantage in that 'gm
antibodies are preferentually detected. This has led to confusion in
subsequent studies evaluating the effectiveness and importance of
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specific IgG. Moreover, the methods used in these studies were not
designed for large-scale routine serology.
ELISA was used successfully to determine the imnunoglobulin class and
titres of specific antibodies to cholera exotoxin and
endotoxin
(215,216)
. Titration of the antiendotoxin antibodies was
done with techniques involving secondary antibody manifestations, like
vibriocidal effects and agglutination, and compared to ELISA which
measures the primary binding of antibodies to solid phase antigen.
Similar titre values were registered with the vibriocidal and the
agglutination techniques, whereas the ELISA, allowing separate
determination of antibodies of different classes, gave titres from 10
to 1000 times higher
(216)
. In a more recent report an assay capable
of detecting antibodies directed against LPS and non-LPS Vibrio
cholerae surface antigens is described
(217)
. Sodium azide-killed
whole cells of V.cholerae were adsorbed to polystyrene tubes and used
as immobilized antigens.
Local antibody formation by plasma cells in E.coli infected rabbit
kidneys has been studied by the ELISA technique 
(218).
 Antibodies
against E.coli 0 antigen, which developed in response to immunization
of rabbits with formalin-killed bacteria, were also measured by
ELISA (219) . Ahlstedt and coworkers have in fact found the ELISA to be
a most useful method in determining antibodies against various E.coli 
antigens. Using the ELISA, they were able to measure antibodies in
the urine of patients with acute pyelonephritis
(220).
After the successful use of ELISA for determining antibody to smooth
LPS, the method was also applied to measure antibody to rough LPS.
The technique was found to be more sensitive than quantitative
precipitation in determining IgG antibodies directed to Salmonella 
minnesota Re glycolipid
(221,222)
. Ito and coworkers attempted to
duplicate the work of Bruins and his asociates
(221) 
to measure
antibodies to the rough LPS of E.coli J5 (223) . They were unsuccessful
and instead found that the rough endotoxin was not adhering in
sufficient amounts to the surfaces of the polystyrene tubes used in
the assay. They were however successful when antigen adherence was
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carried out in the presence of 0,02M magnesium chloride. It is not
known how magnesium ions mediate the adherence of rough J5 endotoxin
to polystyrene. Gonococcal LPS was also found to require magnesium
ions in order to adsorb to polystyrene.
ELISA has recently been found to be a sensitive and highly
reproducible method of measuring anti-lipid A antibody
(22,225)
. The
technique was used to measure antibodies to lipid A in the serum of
patients with urinary tract infections
(212).
ELISA is reported to be an excellent method of screening populations
226) .for brucella antibodies 
(226).
	for total anti-brucella
antibodies (IgG + IgM + IgA) in the sera of patients with brucellosis
gave readings that were more than double those found in hundreds of
control sera.
In the studies discussed so far, the ELISAs were carried out in
polystyrene tubes. However, in situations where large numbers of
samples are to be assayed, a microtitre ELISA is more appropriate.
Young and coworkers describe a microtitre assay for measuring
immunoglobulin G cholera antitoxin in humans serum
(227,228)
. The
assay was found to be specific, sensitive and reproducable and only
needed as little as 5 ul of serum. The method is said to be
particularly well suited to seroepidemiological surveys. A microtitre
ELISA was also used to measure group B streptococcal antibodies
(IgG) (229) .
In conclusion, it is hoped that ELISA by giving more sensitive
measurements of antibodies will lead to a greater understanding of the





3.1 MEASUREMENT OF ANTIENDOTOXIN ANTIBODIES IN HUMAN SERUM BY ELISA
3.1.1 Introduction 
The indirect ELISA was used for the measurement of antiendotoxin
antibodies in human serum. The basic procedure is outlined below:
(a) Antigen is attached to the solid phase and then washed.
(b) Test serum, diluted as required, is added and incubated at a
standard temperature and time. This facilitates the attachment
of any specific antibodies to the antigen. This is followed by
washing.
(c) Enzyme labelled anti-antibody is added and allowed to react with
the treated plate and then rinsed.
(d) Substrate to the bound enzyme is added. Degradation of substrate
results in a colour change. The reaction is stopped after an
appropriate period of time and the amount of colour change is
related to the amount of antibody in the test sample.
Human serum samples were provided by the Natal Blood Transfusion
Service from blood units donated by volunteers in the Natal Province.
Before use, the serum was centrifuged for 5 minutes at 16 000 rpm and
then diluted 1:50 with 0,9% sodium chloride solution. Saline
solutions and water used throughout the study were sterile and pyrogen
free (Sabax Laboratories, Johannesburg). Only Analar reagents were
used in the preparation of buffer solutions.
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3.1.2 The binding of endotoxin to microtitre plates 
Endotoxins (Difco Laboratories, Detroit) from the following 12
bacterial strains and species were used : E.coli 055:B5, E.coli 
0127:B8, E.coli 0128:B12, E.coli 026:B6, E.coli 0111:B4, Sh.
flexneri, S.minnesota 9700, S.abortus equi, S.marcescens, S.typhosa,
S.typhimurium and S.enteritidis.
A mixture of endotoxins was used to coat microtitre plates according
to the materials and methods section of the publication: Gaffin,
S.L., Badsha, N., Brock-Utne, J.G., Vorster, B.J. and Conradie, J.D.
An ELISA procedure for detecting human anti-endotoxin antibodies in
serum
(230)
. A copy of this publication is appended to this thesis.
3.1.3 ELISA technique
(a) 50)ul of the diluted serum samples were applied to the wells of
the coated microtitre plates. Serum samples were also introduced
into blank wells. The plates were incubated for 1 hour at 45 °C.
(b) The plates were then emptied, washed with TST buffer, pH 8,0
(0,05 M tris-0,1M NaC1 with 0,02% Tween 20 and 0,02% sodium
azide, NaN 3 , as a preservative) and dried.
(c) Conjugate consisting of sheep anti-human antiendotoxin antibodies
and horseradish peroxidase was prepared according to the method
of Wilson and Nakane (231) by the Natal Blood Transfusion Service.
It was diluted (usually between 1:50 and 1:100 depending on the
batch of conjugate used) in saline and 50)11 were pipetted into
each well of the microtitre plates and left to incubate for 1
hour at 45°C.
(d) The plates were then emptied and rinsed as in (b) above.
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(e) 50 yl chromogenic substrate were pipetted into each well. Colour
was allowed to develop for 30 minutes, in the dark, at room
temperature. Chromogenic substrate was made up of 18,4 mM
Na 2B407 .10H 20 (Borax, 0,70g), 30,5 mM succinic acid (0,36g), 3,7
mM 0-phenylene diamine (40mig), 4,0 mM urea hydrogen peroxide (40
mg) and distilled water to 100 01 (232) . It was provided by the
Natal Blood Transfusion Service.
(f) The enzymic reaction was stopped by adding 150 )-11 1 N
hydrochloric acid to each well.
(g) The intensity of colour developed in each well at 492 nm was
measured using a photometer (Vitatron DCP, Holland).
3.2 IMMUNOPRECIPITIN TECHNIQUE
Serum endotoxin-specific antibodies were also measured by an
immunoprecipitin procedure, adapted from Gaffin and coworkers (18) .
(a) Cyoprecipitates were removed from serum samples by centrifuging
the samples at 7 000 rpm for 30 minutes, incubating them
overnight on ice and centrifuging them again, to clarify, at 7
000 rpm for 30 minutes, before use.
(b) A mixture of endotoxins obtained from 5 bacterial strains (E.coli 
055:B5, S.minnesota 9700, S.typhimurium, S.typhosa and
S.enteritidis; Difco) were dissolved in water at a final
concentration of 1 mg/ml.
(c) 300 pl of the serum samples were added to 100)11 of the endotoxin
mixture and 1001 1M phosphate buffer (NaH 2PO4/Na2HPO4), pH 7,3.
Controls were set up in which serum samples were added to 100,u1
distilled water and 10 pl 1M phosphate buffer, pH 7,3. All
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samples were tested in triplicate. The solutions were incubated
for 2 hours at 37°C and then left overnight at 4 °C.
(d) The solutions were then centrifuged in the cold for 20 minutes at
16 000 rpm and the supernatant fractions were discarded.
(e) The precipitates were washed twice with 1 ml ice-cold phosphate
buffered saline, PBS (0,8% NaC1, 0,02 M NaH 2PO4/Na2HPO4)pH 7,3.
(f) The protein was then determined using a Coomassie blue stain
assay (233) . 0,5 ml Coomassie blue reagent* was added to each of
the precipitates. The intensity of the colour which developed
after leaving the samples at room temperature for 20 minutes, was
read in a photometer at 600 nm. The amount of protein present
was then determined from a standard curve obtained by adding
bovine serum albumin, BSA, (0 to 200 )ug) to Coomassie blue
reagent.
*Preparation of Coomassie Blue reagent 
50 mg of Coomassie blue (Brilliant blue G, Sigma, St.Louis) was
added to 25 ml ethanol (95%) and mixed for 1 hour after which 50
ml phosphoric acid (85%) was added and the solution was stirred
well and filtered before use.
3.3 EXTRACTION OF BACTERIAL ENDOTOXINS
3.3.1 Introduction
During the latter half of the study it was found that commercially
prepared endotoxin from Shigella flexneri was no longer available. It
therefore became necessary to extract the endotoxin in our laboratory,
using the basic phenol-water procedure described by Westphal and
coworkers (33) . Some modifications suggested by other workers were
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incorporated into the method which is described belo0 34) . The basic
principle of the method is that proteins and lipoproteins are
dissolved in the phenol phase while the upper water phase contains the
liberated lipopolysaccharides and polysaccharides together with
nucleic acids.
3.3.2 Cultivation and harvesting 
A stock culture, made up of a mixture of Shigella flexneri strains,
was obtained from Professor H.J. Koornhoff of the South African
Institute of Medical Research, Johannesburg. This stock was cultured,
by B.J.Vorster of the Blood Transfusion Service, Pinetown, in a
trypticase soy broth (Biolab, Pretoria) for 5 days at 35°C, with
constant agitation. The bacteria were killed by autoclaving and
harvested by centrifugation for 30 minutes at 3 000 rpm.
3.3.3 Extraction procedure
(a) 60 ml distilled water were added to 10 g (wet weight) of
bacteria. The suspension was brought to 70°C with constant
stirring.
(b) After a homogenous suspension had been obtained, 60 ml 90%
phenol, which had been preheated to 70 °C, were added.
(c) The mixture was stirred for 15 minutes at 70°C and the solution
was distributed to glass centrifuge tubes, which were then chilled
in an ice bath overnight to allow the phases to separate.
(d) The tubes were centrifuged at 5 000 rpm for 15 minutes at 4 °C.
(e) The aqueous supernatant phases were saved and 60 ml distilled
water were added to the combined phenol phases and the extraction
was repeated as described in (c) and (d) above. The second
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aqueous phase was combined with the first, and the phenol residue
was discarded.
(f) The aqueous phase was dialyzed at 4 °C for at least 24 hours
against several charges of distilled water.
(g) The solution was then concentrated at 4 °C, by an ultrafiltration
technique, in the dialysis bag, to approximately 1/9th of its
original volume using Aquacide II (sodium salt of
carboxymethylcelluslose, Calbiochem-Behring Corporation,
Lucerne).
(h) To this concentrated solution at 4 °C was added dropwise with
stirring 60 ml pre-cooled methanol, which contained 1% volume of
20% magnesium chloride in ethanol. After the suspension was left
overnight at 4°C, the precipitate was collected by centrifugation
at 10 000 rpm for 10 minutes and dissolved in 20 ml cold distilled
water.
(i) To this solution at 4 °C was added dropwise with stirring 40 ml
cold methanol, which contained 0,1% volume of 20% magnesium
chloride in ethanol. The precipitate was collected as described
in (h) above and dissolved in 12 ml distilled water.
(j) The endotoxin solution was frozen and lyophilized.
The endotoxins extracted were found to be protein-free, as assayed
by the Coomassie blue procedure.
3.3.4 Assessment of endotoxin activity
Assays of the activity of each batch of Sh.flexneri endotoxin were
carried out:-
When serum high in antiendotoxin antibody (as determined by ELISA) was
preincubated with the prepared Sh.flexneri endotoxin (50 )Jg/ml) at
37°C for 30 minutes and then assayed, the ELISA was significantly
reduced.
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In addition, test plates were coated with different concentrations (1,
10, 30, 100 and 300)1g/m1) of the prepared Sh.flexneri endotoxin and
the ELISA was carried out with serum high in antiendotoxin antibodies.
The intensity of the colour was found to depend on the concentration
of endotoxin coating the wells.
3.4 RELATIVE ACTIVITY OF LG -1* ANTIBODIES
LG-1 was diluted 1:800 in 0,1M NaC1 containing 0,05 M Tris adjusted to
pH8,0 and also containing 2% each of sheep and bovine serum (obtained
from the Natal Blood Transfusion Service). The assay was carried out
on microtitre plates coated with only one of each of the following
endotoxins separately: E.coli 055:B5, E.coli 0127:B8, E.coli 
0128:B12, E.coli 0111:B4, E.coli 026:B6, S.minnesota, Sh.flexneri,
S.abortus equi, S.marcescens, S.typhosa, S.typhimurium and
S.enteritidis. Several wells on every plate were coated with LPS from
Sh.flexneri to use as a reference standard. The plates were incubated
with 1% bovine serum albumin, BSA, (100)ul/well) at 37 °C for 1 hour,
rinsed with 500 ml TST buffer and dried before being used in the
ELISA.
*Plasma units with high concentrations (>40 fag/ml) of antiendotoxin
IgG were pooled and fractionated, by the Natal Blood Transfusion
Service, to obtain a gamma globulin - Lot LG-1.
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3.5 DIFFERENTIAL ABSORPTION EXPERIMENTS
LG-1 was preincubated with a variety of endotoxin-containing solutions
and then tested for antibody activities remaining. LG-1 was diluted
1:800 in 0,1M NaCl containing 0,05M Tris adjusted to pH 8,0 and also
containing 2% each of sheep and bovine serum. This solution was used
in the following incubations all carried out at 37 °C for 10 minutes,
after which the samples were stored on ice. In each case endotoxin
was added to a final total concentration of 50 .pg/ml.
(a) The diluted LG-1 was incubated separately with each one of the
following endotoxins: E.coli 055:B5, E.coli 0127:B8, E.coli 
0128:B12, E.coli	0111:B4, E.coli	026:B6, S.minnesota,
Sh.flexneri, S.abortus equi, S.marcescens, S.typhosa,
S.typhimurium and S.enteritidis.
(b) Diluted LG-1 was incubated with a mixture of all twelve
endotoxins, each at a concentration of 4,16 )pg/ml.
(c) Diluted LG-1 was incubated with mixtures of eleven of the above
twelve endotoxins by omitting each one in turn.
(d) As controls the diluted LG-1 was incubated with 0, 1M sodium
acetate buffer, pH 5,0.
The above absorbed LG-1 samples were centrifuged at 4°C for three
minutes at 16 000 rpm. They were then assayed for antiendotoxin
antibodies by means of the ELISA procedure previously described. The
assay was carried out on two types of microtitre plates: those coated
with only one of each of the above endotoxins separately, and those
coated with a mixture of all 12 endotoxins. The plates were incubated
with 1% bovine serum albumin, BSA, (100 )11/well) at 37 °C for 1 hour,
rinsed with 500 ml TST buffer and dried before being used in the
ELISA.
74
Preliminary experiments had been conducted in order to establish the
optimal time required for preincubation of LG-I with endotoxin. LG-I
was preincubated with endotoxin for periods ranging from 15 seconds to
5 hours; it was found that the reaction occurred within seconds and
had reached conclusion by 10 minutes.
Similarly, IJG-1 was preincubated with different endotoxin
concentrations (1, 10, 30, 50 and 75 pg/ml) before it was established





4.1 SPECIFICITY OF ELISA FOR ANTIENDOTOXIN ANTIBODIES
Three high-titre serum samples (as determined by ELISA) were
preincubated with a mixture of endotoxins (E.coli 055:B5, S.minnesota,
S.typhimurium, S.typhosa and S.enteritidis) at a final concentration
of 10 ,pg/m1 and 100 ,pg/ml, for 1 hour at 37
°C. When subsequently
assayed, the ELISA was either greatly reduced or negative for serum
preincubated with endotoxin at both concentrations. The results are
shown in table 7.
It is assumed that the antiendotoxin antibodies present in these
samples were bound to the added endotoxins and were therefore
unavailable to bind to the endotoxin coating the microtitre plates,

























































































4.2 ENDOTOXIN COATING OF MICROTITRE PLATES
A solution of a mixture of endotoxins (E.coli 055:B5, S.minnesota,
S.typhimuriu ►, S.typhosa and S.enteritidis), at the following
concentrations, 0,001; 0,01; 0,1; 1,0; 10,0; and 100 jug/ml, was
adsorbed on to the surfaces of the wells of the microtitre plates.
Three high titre serum samples (as previously determined by ELISA)
were assayed at each of the above endotoxin concentrations, using the
standard ELISA technique. The intensity of the final colour was found
to depend on the concentration of endotoxin coating the wells.
For all three samples, at endotoxin concentrations less than 10)ag/m1
the colour intensity was low, but at 10pg/m1 and higher, the optical
density increased substantially, as shown in Figure 10. For reasons
of economy, all subsequent experiments in this study were carried out












0 0,001 0,01 0,1 1,0 10 100
Endotoxin concentration (pgirnI)
Figure 10. Effect, on ELISA colour development, of varying endotoxin
concentration.
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4.3 CALIBRATION OF THE ELISA
Serum sample number 104 was found to have an antiendotoxin antibody
concentration of 44,4 pg/m1 according to the immunoprecipitin 
technique described on page 58. Sample 104 was then diluted with 0,1M
sodium chloride and tested by ELISA at various concentrations, as
shown in Figure 11.
The optical density curve was divided into four regions for easy
visual evaluation as 0, 4, 44, and 717q, which correspond to
antiendotoxin antibody concentration ranges of 0 - 2,5 )1g/ml, 2,5 -5
)ag/ml, 5 - 40 dug/ml, and greater than 40 dug/ml, respectively.
1,4
1,2-
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Figure'll. Calibration of the ELISA.
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4.4 DISTRIBUTION OF ANTIBODY CONCENTRATION
Sera from 48 blood units (supplied by the Natal Blood Transfusion
Service) were screened for antiendotoxin antibodies using the ELISA
described on page 67. Subsequently, large numbers of serum samples
were similarly assayed by Mrs Maureen Rome in our laboratory. All
blood units donated to the Natal Blood Transfusion Service are now
routinely screened for antiendotoxin antibodies at their Pinetown
ELISA laboratory.
Figure 12 shows the distribution of antiendotoxin antibody titres
among 1051 blood units (230) . 42% of the units tested had
antiendotoxin antibody concentrations of zero to 2,5,0ag/ml, 31,7% had
2,5 - 5 ,pg/M1, 16,8% had 4 - 40 ,pg/m1 and 8,3% had a antiendotoxin
antibody concentration greater than 40 jig/ml. Plasma units with
concentrations of antiendotoxin IgG above 40 jag/m1 are pooled and
fractionated to obtain gamma globulin. It had previously been found
that antibody concentrations of 40pg/m1 and above are therapeutically
useful in cats (18) . One technician working with automatic pipetting
and optical reading equipment is able to screen 200 serum samples per
day or 50 000 per year. With an effective recovery of 7% this
provides 3500 units or approximately 700 litres of high-titre plasma
per year (B.J. Vorster, pers. come).
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Figure 12. Distribution of an4eAdotoxin antibody concentrations in
1051 plasma samples ''' .
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In Natal, blood units containing high concentrations of specific
antibodies (>40 )1g/ml) were found with a frequency of 3,6% among all
white donors (n = 1658) and 10,35% among all African donors (n = 2482,
X2 = 55,4, p < 0,01) (234) . The White male and female donors had no
significant differences between them but the African women had almost
twice the frequency of high titre serum as the African men (14,4%
versus 7,6%, respectively, X 2 = 29,1, p < 0,01)
It was then decided to investigate the levels of serum antiendotoxin
antibodies in Natal Indians to see if there were significant
differences between the sexes. 148 serum samples obtained from the
Chemical Pathology Laboratory of the R.K. Khan Hospital in Durban were
screened for antiendotoxin antibodies. These samples were all from
Indian hospital patients.
Indian warren patients were not found to have a higher frequency of
high titre serum than the Indian male patients. 10/97 female patients
and 3/51 male patients had serum antiendotoxin antibody concentrations
above 40 iug/m1 (10,3% versus 5,9% respectively, x
2 = 0,82, p = 0,25).
The distribution of antiendotoxin antibody concentrations in the serum















Figure 13. Antiendotoxin antibody levels in male and female
patients at R.K. Khan. Hospital, Durban.

















4.5 SPECIFICITY OF HIGH TITRE SERA FOR VARIOUS ENDOTOXINS
Microtitre plates were coated with individual endotoxins (10 )pg/m1)
obtained from 12 different bacterial species and strains. Serum
samples previously found to be high in antiendotoxin antibody titres
( >40 pg/m1) were tested by ELISA on these plates. The height of each
bar in Figure 14 represents the antibody concentration measured in 12
serum samples. Each sample was found to have its own characteristic
specificities. Most samples were found to react strongly with
S.typhimurium, S.enteritidis and Sh. flexneri but poorly with
S.marcescens, E.coli 0111:B4, E.coli 027:B8 and S.minnesota.
EC EC EC EC EC
SAMPLE 055 027 0128 026 0111 SH. S. S. AB. S. S. S. S.
NO. B5 B8 B12 B6 B4 FLEX. MINN. EOUI. MARC.TYPHI TYPHQ ENT.
Figure 14. Specificities of antiendotoxin antibodies in 12 high-titre
serum samples.
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4.6 RELATIVE ACTIVITY OF LG-1 ANTIBODIES
The ELISA colour development, and, hence, the binding of LG-1
antibodies to 14 different endotoxins is shown in Figure 15. Binding
was found to be highest with endotoxin from Shigella flexneri,
S.abortus equi and S.typhimurium, intermediate with S.enteritidis 
E.coli 026:B6, K.pneumoniae and P.aeruginosa. Binding with the other
endotoxins was relatively low but reproduceable.
The activity of the LG-1 antibodies to endotoxin from K.pneumoniae and
P.aeruginosa was determined by B.J. Vorster of the Natal Blood
Transfusion Service(235).
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Figure 15. The relative binding capacities of LG-1 antibodies to
endotoxins from 14 bacterial species and strains.
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4.7 COMPARISON OF LG-1 ANTIBODY ACTIVITY TO THAT OF NORMAL HUMAN
IMUNOGLOBULIN
The activity of the LG-1 antibodies was compared with that of normal
human immunoglobulin preparations obtained from the National Blood
Fractionation Centre, Pinetown. Two gamma globulin fractions were
tested, standard globulin 1 (Batch G-25, manufactured October, 1981)
and standard globulin 2 (Batch G-27, manufactured, November, 1981).
They were diluted and assayed in the same manner as the LG-1
preparation. The results, shown in Figure 16 indicate that the
antibodies in the standard gamma globulin preparations bind to most of
the endotoxins tested but to a considerably less extent than the LG-1
antibodies. The binding capacity of the antibodies in the standard
globulin preparations towards most of the endotoxins tested was less
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Figure 16. Comparison of LG-1 with standard globulin preparations.
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4.8 COMPARISON OF LG -1 ANTIBODY ACTIVITY TO THAT OF AN
ANTI -PSEUDOMONAS IMMUNOGLOBULIN, GX -9
The activity of the LG-1 antibodies was similarly compared with that
of an anti-pseudomonas immunoglobulin fraction, GX-9, prepared by
Wellcome Laboratories, England.
The results, shown in Figure 17 clearly show that the binding capacity
of the DG-1 antibodies towards the endotoxins tested is considerably
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Figure 17. Comparison of LG-1 with an anti-pseudomonas immunoglobulin, GX-9.
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4.9 PRESENCE OF CROSS-REACTING AND "SPECIFIC" ANTIBODIES
Differential absorption experiments show that the LG-1 anti-LPS
antibodies are a mixture of cross reacting as well as specific
antibodies. This is illustrated by the following examples:
LG-1 gamma globulin was first incubated with endotoxin prepared from
Shigella flexneri and then assayed on plates which had been coated
with all 12 endotoxins. The colour developed in the ELISA procedure
was found to be only 60% of that of the untreated control i.e. of the
colour developed by LG-1 antibodies binding all 12 endotoxins, 40% was
reduced by absorption by Shigella flexneri endotoxin. LG-1 was also
incubated with all the other endotoxins at one time, excluding 
Shigella flexneri endotoxin. In this case the colour developed was
30,7% of the untreated control. This 30,7% is the colour produced by
those antibodies reacting specifically with Shigella flexneri 
endotoxin and not with any of the other endotoxins being tested. The
remaining antibodies (9,3%) were cross-reactive.
These results were confirmed by those obtained from assays carried out
on plates coated only with Shigella flexneri endotoxin. When Shigella 
flexneri endotoxin was incubated with LG-1 prior to assay, the
activity was reduced to 6,1% of the untreated control. However, when
LG-1 was pre-incubated with the other 11 endotoxins minus Shigella 
flexneri 91,7% of the activity was retained. Antibodies which bound
to only Shigella flexneri endotoxin were not absorbed and these could
bind to the Shigella flexneri endotoxin coating the plates. Thus a
large proportion of antibodies binding to Shigella flexneri endotoxin
were mainly specific, however some cross-reactivity is also seen (see
Figure 18). Comparable results were obtained with E.coli 026:B6
endotoxin. As shown in Figure 18, 21,0% of the total antibodies
absorb E.coli 026:B6 endotoxin; of these however, approximately half
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Figure 18. The specificities of LG-1 antibodies to endotoxins
prepared from 12 bacterial species and strains.
93
48,86% of the total antibodies were found to bind to salmonella 
typhimurium endotoxin. When LC-1 was incubated with the other 11
endotoxins omitting S.typhimurium, the colour developed on the 12
endotoxin plates was reduced to only 10,67% of the untreated control.
Similarly, when this preincubated sample was assayed on plates coated
only with S.typhimurium endotoxin, the activity was reduced to 10,5%
of the untreated control. Apparently most of the antibodies in LC-1
which react with S.typhimurium endotoxin also bind to the other
endotoxins added to the incubation mixture and therefore have been
absorbed out, leaving the relatively few specific antibodies, which
bind to the S.typhimurium endotoxin coating the plates. From these
experiments it was concluded that the antibodies binding to
S.typhimurium are largely cross-reactive (78,16%) with, however, some
specific antibodies (21,84%) being present. From Figure 18 it can be
seen- that the antibodies which bind the endotoxins of all the other
salmonella species tested (S.abortus equi, S.enteritidis, S.typhosa,
S.minnesota) are also largely cross-reactive.
LG-1 antibodies to endotoxins prepared from Serratia marcescens,
E.coli 0128:B12 and E.coli 0111:B4 are also mainly cross-reacting.
Endotoxins from E.coli 055:B5 and E.coli 0127:B8 are bound only by
cross-reacting antibodies. For example, 6,94% of the total antibodies
bind E.coli 055:B5 endotoxin. When LG-1 was incubated with the other
11 endotoxins except E.coli 055:B5 endotoxin, the activity on the 12
endotoxin plate was reduced to zero, i.e., there are no antibodies
which exclusively bind E.coli 055:B5 endotoxin.
The specificities of all 12 endotoxins tested are summarized in Figure
18 and table 8.
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Table 8 















Mainly specific and few
cross-reacting
Specific and cross-reacting in
approximately equal proportion






5.1 DISCUSSION OF RESULTS
In recent years antibody therapy for the treatment of Gram-negative
bacteraemia and endotoxaemia has become an experimental adjunct to
conventional antibiotic treatment in a very few centres. The
principal limiting factor in the past has been the problem of
accumulating sufficiently large stocks of human antiendotoxin
antibodies. Braude's group used antibodies, raised by vaccination of
healthy volunteers with heat-killed Gram-negative bacterial mutants
for their highly succesful clinical trials (13-15) . Large stocks of
antibodies have not yet however been produced in this manner since
immunization with the.endotoxin "core" has negative side effects (17) .
This problem was overcome in a simple way by screening units of blood
donated to a blood bank in order to identify those units which have a
high concentration of naturally occurring antiendotoxin antibodies.
The high-titre plasma units are pooled and endotoxin specific gamma
globulin is prepared from them (as was the case with Lot LG-1), or
alternatively individual units may be freeze-dried. The ELISA
technique used to measure concentrations of antiendotoxin IgG in the
blood samples has proven to be highly specific for these antibodies.
Furthermore this procedure could be used by most blood banks since it
is relatively inexpensive and does not necessarily require
sophisticated equipment.
Individual serum samples, found by ELISA to be high in antiendotoxin
IgG, were each seen to have their own characteristic specificities
towards different endotoxins. When many high-titre serum samples were
pooled and fractionated, the gamma globulin product (i.e. DG-1) was
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found to have the ability to bind to a range of endotoxins as shown in
Figure 15. This is in contrast to immunoglobulins raised against
specific endotoxins; for example, the Wellcome Laboratory GX-9
anti-pseudomonas immunoglobulin preparation did not show significant
binding capacity towards the range of endotoxins tested in this study
(see Figure 17). The DG-1 gamma globulin also had a far greater
capacity to bind endotoxins compared to standard globulin preparations
manufactured by the National Blood Fractionation Centre, Pinetown (see
Figure 16).
The concentrations of endotoxin-specific antibodies in the blood of
different South African population groups has been examined. African
donors were found to have a greater incidence of high-titre
antiendotoxin antibodies compared to White donors (234) . This may be
related to Pudifin and Duursma's findings of higher levels of
circulating immune complexes in Black blood donors than in White or
Indian donors (236) . African warren were, in turn, found to have almost
twice the frequency of high titre serum as African men (234) . However,
no significant differences in serum antiendotoxin antibody levels were
established between Indian male and female hospital patients sampled
in this study. Further studies may be necessary to fully understand
racial as well as sex differences in antiendotoxin antibody titres.
The differential absorption experiments carried out in this study
clearly showed that the LG-1 antiendotoxin gamma globulin is a mixture
of cross-reacting as well as specific antibodies. Antibodies which
bind to Shigella flexneri endotoxin were found to be largely specific.
Those antibodies reacting with E.coli 026:B6 endotoxin were found to
be specific and cross-reacting in approximately equal proportions.
Antibodies to the salmonella species, Serratia marcescens and
remaining E.coli species tested were in the main non-specific. The
relatively non-specific nature of the LG-1 antibodies is of advantage
in that the preparation can be used to treat endotoxaemia resulting
from a range of different endotoxins i.e. it does not act exclusively
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with only one or two bacterial strains. Differential absorption
experiments had also been carried out on selected high-titre serum
samples (234) . A mixture of cross-reacting and specific antiendotoxin
antibodies were also found in these individual serum samples.
The "natural" antiendotoxin antibodies present in the high-titre blood
samples are presumed to be raised by the donors as a result of
previous subclinical infections or due to autoimmunization from
occasional intestinal bacteria or endotoxins entering the circulation.
One would therefore expect some correlation between the specificities
of the LG-1 antibodies and the frequency of different Gram-negative
bacteria in the environment. An attempt was made to relate the
relative binding activities of the LC-1 antibodies to the reported
incidence of various Gram-negative bacteria in blood cultures taken
from hospital patients in the area covered by the Natal Blood
Transfusion Service.
Figure 19 relates the activity of the LG-1 antibodies (as determined
by the relative binding capacity towards the various endotoxins
studied) to the incidence of these Gram-negative organisms in blood
cultures taken from patients at the King Edward VIII Hospital, Durban,
during 1981 (96) .
The specificities of the LC-1 antibodies towards endotoxins from
various Gram-negative bacteria do not in most cases reflect the
incidence of these organisms in the blood cultures. For example, LG-1
is high in Shigella flexneri binding antibodies but the incidence in
the blood cultures of this species is virtually nil. The incidence of
S.typhosa in blood cultures is high; however the binding capacity of
DG-1 antibodies towards S.typhosa is relatively low. In contrast,
antibodies are abundant towards most of the other salmonella species
studied (e.g., S.typhimurium, S.abortus equi, S.enteritidis);  however
these species are far less commonly encountered in blood cultures. In
the case of E.coli and Pseudomonas there appears to be some
cv
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Figure 19. Comparison of LG-1 activity and the frequency of
Gram-negative isolates from hospital blood cultures
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Shigella is a common cause of intestinal infection but rarely gives
rise to bacteraemia; the anti-shigella antibodies reported in this
study may be important in restricting the growth of this species in
the blood stream and preventing bacteraemia. In a study reported in
1960, Roantree and Rantz examined the heat-labile bactericidal effect
of human serum (237) . Almost all the sera tested by them showed the
ability to kill Shigella dysenteriae at the rate of 1 x 10
7 to 1,5 x
10
8 
organisms/M1 of serum in two hours. They also found that a high
proportion of the shigella and klebsiella strains tested were
sensitive to killing by serum, in contrast to a higher percentage of
resistant salmonella strains. There appears to be a limitation to the
numbers of strains capable of causing bacteraemia and one of the
limiting factors maybe the amount and specificity of the antiendotoxin
antibodies present in the host's serum.
Further studies are needed for a deeper understanding of the
antiendotoxin antibody specificity. For instance, there may be a high
correlation between stool isolates and specific antiendotoxin antibody
concentrations.
Gaffin has suggested that the toxic effects of endotoxin may be
reduced by specific antibodies by three mechanisms (238) : (a)
antibody may bind to the active site of the endotoxin molecule (or
close to it) thereby blocking its toxic actions (b) the complex
formed between the antibody and endotoxin may be removed from the
circulation much faster than endotoxin alone, i.e. the antibody may
have an opsonizing effect (c) the binding of antibody to the
bacteria activates complement which, in turn, damages the surface
membranes of the organisms, leading to their increased permeability,
swelling and lysis. In vitro, treatment of Klebsiella pneumoniae with
antiendotoxin antiserum caused the cells to agglutinate and form a
sticky mass (239) . This required the presence of complement. Electron
microscopy showed that the surface membranes of the Klebsiella had
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been damaged. Thus, the antiserum appears not only to bind to the
endotoxins but also leads to the rapid destruction of Gram-negative
bacterial cells (240)
In an important study Vorster and coworkers found that mice treated
with LG-1 antibodies prior to inoculation with Pseudomonas aeruginosa
were significantly protected against morbidity and mortality as
compared with saline treated controls
(241)
. LG-1 reduced the
mortality from 75% to 8% and the morbidity index from 58 to 16.
LG-1, when given prophylactically, was also shown to reduce the
abortifacient effect of low doses of E.coli on pregnant rats
(242) .
The mean weight of the foetuses of the LG-1 treated rats was
1,132g+,0,12g compared to a mean weight of 0,581g+0,3g for the
foetuses of the control rats (p<0,005).
Shock was induced in-rabbits by a 60 minute occlusion of the superior
mesenteric artery. Animals which had been treated two days prior to
shock induction with antiendotoxin antibodies had a greater rate of
survival (7/8; 87,5%) 10 days post shock compared to control animals
(2/12; 16,7%) (243).
In view of these successful animal studies Gaffin and coworkers have
undertaken numerous clinical studies to test the effectiveness of
antiendotoxin immunotherapy in the management of endotoxaemia of
different origins. The results of some of these studies are
summarized below.
5.2 THE USE OF ANTIENDOTOXIN ANTIBODIES IN THE TREATMENT
OF SEPTIC SHOCK IN HUMANS
Twenty-two consecutive patients who were in septic shock or imminent
septic shock were treated with antiendotoxin antibodies (244) . The
antibodies were administered either intramuscularly in the form of
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LG-1 or intravenously in the form of an anti-LPS antibody-rich
freeze-dried plasma, FDP, both provided by the Natal Blood Transfusion
Service, Pinetown. The patients included in this study had a variety
of primary conditions including severe peritonitis and septic shock
due to typhoid perforation of the bowel, Hodgkin's disease complicated
by sepsis and shock lung and septic shock following pyelonephritis in
pregnancy. Twenty of these patients showed complete or temporary
improvement in clinical signs. Of the two patients who did not
respond at all to antiendotoxin antibody administration one was a
child with complete bone marrow failure and severe sepsis and the
other was a patient who had brain trauma and it is suggested that his
condition might not have been due to septic shock but to the central
nervous system damage.
In keeping with these preliminary results are those reported in a
separate study in which anti-LPS antibody-rich freeze-dried plasma was
used to treat patients in septic shock of obstetrical and
gynaecological origin (245) . The patients included in this study were
in shock mainly as a result of septic abortions, puerperal sepsis,
pyelonephritis in pregnancy or pelvic abscesses. Significant in this
study were the stringent criteria used for their definition of shock.
Patients were included in this study if they had
(a) pyrexia greater than 38,5°C
(b) an obvious septic focus and
(c) a systolic blood pressure 80 inn Hg after resuscitation to a
central venous pressure 6 cm H20.
The control patients received conventional therapy which included
replacement of plasma and blood volume, correction of electrolyte and
acid base imbalances and the use of antibiotics.
Patients in the study group received similar treatment as well as the
intravenous administration of the antibody rich reconstituted
freeze-dried plasma. In this Anti-LPS treated group, only 1/14 (7,1%)
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patients died while of the control patients, 9/19 (47,4%) died. They
found that the antiendotoxin antibody treatment caused the mean
arterial pressure (MAP) to rise 24,0 mm Hg from 45,11+7,36 mm Hg to
69,1+9,07 (t = 6,87; p < 0,001) within a period of 75 minutes from
administration. Significantly the development of complications due to
septic shock was greatly reduced in the experimental group of
patients. In addition the survivors in the control group had a much
longer stay in hospital of 28,1 days while those who received antibody
therapy had a mean stay of only 14,2 days (p < 0,05). It is hoped
that the future widespread use of antiendotoxin antibody therapy in
the management of septic shock will decrease the overall mortality
rate.
In addition to the human antibody preparations, antiendotoxin
hyperimmune equine serum has also been, produced by vaccination of
ponies
(246)
. The hyperimmune serum has been used in the veterinary
field as well as in studies on the treatment of pseudomonas keratitis
in rabbits and the treatment of radiation sickness in mice. These
studies are summarized below.
5.3 THE USE OF ANTIENDOTOXIN HYPERIMMUNE EQUINE SERUM
5.3.1 Veterinary applications 
5.3.1.1 Septicaemia in horses
Hyperimnune equine serum was used successfully to treat the endotoxin
mediated diseases colitis X and peritonitis in horses 
(246) . The
antibody rich serum was also effectively used during a gastroenteritis
epidemic among foals. Of the 21 foals which received hyperimmune
serum (i.v.; 250 ml serum per foal) all completely recovered within 48
hours and subsequently grew normally. 43 foals received the
conventional therapy; two died and the remainder needed up to 10 days
to recover. Many of these foals subsequently showed stunted growth.
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5.3.1.2 Surface infections in horses
The hyperimmune serum was also used topically to successfully treat
two mares with intrauterine klebsiella infections
(246) . The
infections had preciously persisted for 12 months and had not
responded to prolonged antibiotic therapy.
5.3.1.3 Surgery prophylaxis
Endotoxaemia and death frequently occur following abdominal surgery in
horses. Hyperimmune serum is now routinely used prior to surgery on
horses and this is reported by veterinary practitioners to have
dramatically improved the post-operative mortality and morbidity rates
of these horses
(246).
5.3.1.4 Prophylaxis in newborn foals
Newborn foals have permeable intestinal walls thus allowing antibodies
present in colostrum to enter the blood stream
(246)
. If, however, the
colostrum does not have sufficient antibodies or the foals receive
colostrum late then the chance of developing septicaemia increases.
Newborn foals were therefore fed per os 250 ml hyperimmune
antiendotoxin serum within a few hours of birth in an attempt to
supplement the colostrum. Only 2/72 foals which received the
hyperimmune serum showed any ill effects while 51/156 of the control
animals developed gastroenteritis.
5.3.2 The treatment of pseudomonas keratitis in rabbits 
Antiendotoxin hyperimmune equine serum has also been found to be
effective in treating corneal pseudomonas infections in rabbits and
guinea pigs (247) . The corneas of rabbits were infected with
Pseudomonas resulting in scarring and opacity. The eyes were treated
by lavage with hyperimmune serum or saline at a rate of 40
1 04
drops/minute, for 5 minutes, three times a day for 8 days. Eyes
treated with hyperimmune serum improved significantly; 13/15 (86,7%)
compared to the saline treated controls 4/17 (23,5%).
5.3.3 The treatment of radiation sickness in mice
Excess ionizing satiation kills cells lining the gut wall increasing
its permeability to bacteria and toxins (243) . These then "leak out"
of the gut into the circulation. In addition, excess ionizing
radiation has an immunosuppressive effect which further reduces the
ability of irradiated animals to counter the effects of invading
bacteria and endotoxin. Mice were X-irradiated with 630 rads and 6
days later were treated with 0,1 ml antiendotoxin hyperimmune equine
serum (i.p.) or saline. The hyperimmune serum reduced mortality
significantly from 71% to 41,1%, compared to controls.
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5.4 CONCLUSIONS
From this brief review of the studies of Gaffin and coworkers it can
be seen that the potentials for the use of antiendotoxin antibodies
are many and varied.
In conclusion, the human antiendotoxin preparations produced by the
method of Gaffin and coworkers have a number of advantages which are
summarized below:
(a) The preparations contain a mixture of antibodies capable of
binding endotoxins from a wide range of Gram-negative
bacteria
(235,240,248).
(b) Their preparation does not involve any immunization procedures.
Large stocks of - antibodies can therefore be accumulated since
there is no risk to human volunteers.
(c) They are relatively inexpensive to produce and therefore could be
available for widespread use.
Studies, both on animals and humans have shown the antibodies to be
effective in the treatment and prevention of many of the toxic effects
of endotoxin and in time to come the antiendotoxin gamma globulin may
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An ELISA procedure for detecting human
anti-endotoxin antibodies in serum
STEPHEN L GAFFIN,• NASI MA BADSHA, J G BROCK-UTNE, B J VORSTER and J D CONRADIE
From the Department of Physiology, University of Natal Faculty of Medicine, Durban, and Natal Blood
Transfusion Service, Pinetown, South Africa
SUMMARY We report an ELISA method suitable for the large-scale screening of blood bank stores
to identify those blood units containing high concentrations of antiendotoxin antibodies. In Natal,
8.3 % of total units collected had antiendotoxin antibodies at concentrations greater than 40 p.g/ml,
values that may be therapeutically useful. We found that one technician could screen enough
samples per year to produce 800 litres of such high-titre plasma.
Introduction
The importance of endotoxin in contributing to
mortality and morbidity in Gram-negative sepsis and
non-septic shock is increasingly recognised.' 3
However, conventional antibiotic therapy is usually
aimed at merely killing bacteria and not at reducing
the amount of the very toxic endotoxin present in the
blood of bacteraemic and endotoxic patients. This
may account for the approximately 50% mortality
in Gram-negative bacteraemia. The use of specific
antibodies directed against a range of endotoxins
would appear to be a possible approach.
Both laboratory animals and humans were
protected, sometimes dramatically, 4 against bacter-
aemia or endotoxaemia by active immunisation
against endotoxins or by passive antibody therapy.'
Mainly logistic difficulties prevent the acquisition of
large stocks of human endotoxin specific antibodies
for large-scale clinical testing. However, we found
in Haifa that screening the stocks of blood units
present in a blood bank provided a yield of approxi-
mately 7% of units containing clinically useful high-
titre antiendotoxin antibody-rich plasma. 5 This
human plasma was sufficiently antibody-rich to
protect cats from a lethal endotoxic shock due to
`irreversible' haemorrhage.' However, the screening
procedure in these studies was an inefficient and
time-consuming immunoprecipitin procedure. Ito and
colleagues') described an enzyme-linked immuno-
sorbent assay, ELISA, I l for antibodies to endotoxin.
•Address for all correspondence: Stephen L Gaffin, PhD,
Department of Physiology, Faculty of Medicine, University
of Natal, PO Box 17039, Congella 4013, South Africa.
We report on a modified procedure that is rapid and
specific and suitable for large-scale automated
procedures.
Material and methods
Saline solutions and water were sterile and pyrogen
free (Sabax Laboratories, Johannesburg). Human
serum samples were those obtained along with
blood units donated by volunteers in the Natal
Province using the facilities of the Natal Blood
Transfusion Service. Samples were usually tested
within three days of collection. Before use the serum
was centrifuged for 5 minutes at 16 000 rpm and then
diluted 1:50 with 0.9 °/'„ NaCI. Endotoxins (Difco)
wew obtained from 12 bacterial strains and species
(E. coli 055: B5; E coli 0127: B8; E. coli 0128: B12;
E. coli 026: B6; E. coli 0111: B4; Shig. flexneri;
S. minnesota; S. abortus equii; S. marcescens; S.
typhosa; S. typhimurium; S. enteritidis). They were
prepared as stock solutions with water (1 mg/ml) and
stored in small volumes frozen until used. The
general ELISA microplate method used here has
been described previously for alpha fetoprotein and
other applications.12 
t3
 Microtitre plates (Dynatech
M l 29B) were coated with a mixture of endotoxins for
2 hours at room temperature. Conjugate consisting
of antibody to human IgG and horseradish peroxi-
dase was made according to the method of Wilson
and Nakane. 1)
Results
ENDOTOXIN COATING OF MICROTITRE PLATES
When a mixture of endotoxins at different concen-
trations was added to the wells of the microtitre
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plate for coating, the intensity of the final colour
depended on the concentration of endotoxin placed
into the wells.
For three different serum samples at endotoxin
concentrations less than 10 p.g1m1 the colour
intensity was low, but at 10 ag/rn1 and higher, the
optical density increased substantially (Fig. 1). For
reasons of economy, all further studies were carried
out at an endotoxin concentration of 10 a
value that provided appropriate colour intensities.
CALIBRATION
Serum sample number 104 was found to have an
anti-endotoxin antibody concentration of 44.4 tig/m1
according to an immunoprecipitin technique.' This
0 0001 0a 01 0
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Fig. 1 Effect of endotoxin concentration during the coating
of microtitre plated on ELISA colour development in three
serum samples.
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sample was diluted with 0.1s4 NaCI and tested by
[LISA at various concentrations, as shown in
Figure 2. For rapid screening purposes the optical
density curve was divided into four regions for easy
visual subjective evaluation of 0, +, and
-1- -4- -t- . These designations corresponded to anti-
endotoxin antibody concentration ranges of 0-2 , 5
p.g/ml, 2.5-5 p_giml, 5-40 ;.i.g/ml, and greater than
40 ;,ig/ml, respectively.
SPECIFICITY OF ELISA FOR ENDOTOXINS
When high-titre serum samples according to [LISA
were preincubated with a mixture of endotoxins for
1 hour at 37'C and then assayed, the ELISA was
negative. Apparently the antiendotoxin antibodies
present hound to the added endotoxins and so were
unavailable to bind to the solid-phase endotoxin.
DISTRIBUTION OF ANTIBODY CONCENTRATIONS
Figure 3 shows the distribution of antiendotoxin
antibody titres among 1051 blood units. The largest
group (42.2%) tested had zero to 2.5 uglml. The
next largest (31 , 7 ') had 2.5-5 A smaller
group tested (16.8°0 had 5 40 ;).g/m1 and the
smallest group had more than 40 4g/ m1 (8.3%), a
value previously found to be therapeutically useful
in cats.'
SPECIFICITY OF HIGH-TITRE SERA FOR VARIOUS ENDO-
roxiNs
Some plates were coated with pure endotoxins
obtained from any one of the 12 different bacterial
species and strains. Samples tested by ELISA on
these plates yielded characteristic reactivities, shown
in Figure 4. The height of each bar represents the
antibody concentration measured in 12 selected                         
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Fig. 4 Specificities of antiendotoxin antibodies toward
entotoxins obtained from 12 different bacterial strains and
species in 12 high-titre (>4) 4g,Ml) plasma samples.
Most samples reacted strongly with S. typhmurium, S.
enteritidis, and Sh. tlexneri but poorly or not at all with
S. marcesens, E. colt 0111:134, E. colt 027:88, and S.
minnesota.
serum samples. Some high-titre samples reacted
strongly against certain strains of E. co/i endotoxin
(eg, 026: B6) but not against others (0111:B4). They
reacted more or less strongly against most of the
species tested but rarely against S. marcesens or
E. cot/ 0111:134, each serum sample having its own
characteristic specificities.
Discussion
A number of controlled studies have shown the
significant therapeutic benefit of passively trans-
ferring human antibodies specific to endotoxins to
appropriate patients with confirmed Gram-negative
bacteraemia or endotoxaemia. Mortality was re-
duced by 50% or even considerably more." In
most of these studies, however, the antibodies were
produced by actively immunising volunteers, a
process requiring the utmost care and control since
i mmunisation is done with endotoxins, endotoxin
mutants, or a Gram-negative bacterial cell wall
extract, a mixture including endotoxins. Endotoxin
is toxic in humans at a concentration of 10-9 glml or
about 10-12 M and thus is at least 1000 times as toxic
as the nerve toxin tetrodotoxin found in puffer fish
(Tetraodontidae), which is no longer toxic at 10 -9m.
Major difficulties in producing large volumes of
human antiendotoxin antibodies are the legal,
practical, administrative, and ethical problems
in dealing with large numbers of subjects using a
potentially hazardous immunogen. These problems
can be avoided by simply screening the blood units
in the blood bank by the above ELISA procedure
and reserving those high-titre units found for treat-
ing endotoxaemia or Gram-negative sepsis. In our
laboratory, one technician working with automatic
pipetting and optical reading equipment can screen
by means of the ELISA described here some 200
serum samples per day or 50 000 per year. With an
effective recovery of 8 °,,„' (Fig. 3) this could provide
4000 units or approximately 800 litres of high-titre
plasma per year. A different published EL1SA
procedure using tubes rather than microtitre plates
and much greater amounts of endotoxin for coating
purposes may be satisfactory in a laboratory but
would be more costly and is not well suited for
large-scale screening. 10 An extrapolation from animal
studies suggests that 3 ml/kg of high-titre (40 a.g/m1)
antiserum may be therapeutically useful." Thus
the minimum annual yield of one technician could
produce enough high-titre plasma to treat ca. 88 800
3-kg neonates or 3800 70-kg adults. A different study
on humans suggests that substantially less hyper-
immune serum would be required, and hence a
much greater number of clinical cases could be
treated. 1
Antibodies found by this screening procedure
bind with endotoxins obtained from a few different
Gram-negative bacteria, each serum sample con-
taining antibodies with its own characteristic
specificities. By pooling a large number of such
high-titre units, the final product obtained had a very
w ide  range of reactivities. Such pooled plasma•
contained antibodies that could bind to Gram-
negative bacteria and together with complement
could lyse them, even those outside the listed range
including Klebsiella pneumoniae. 15 We have pre-
viously shown that such high-titre serum found by
screening in a blood bank is effective therapeutically
in treating cats in a lethal endotoxaemia secondary to
a haemorrhagic shock.' Presumably human serum
would be at least as effective in humans, and
controlled double-blind clinical trials of this
material are now in progress. Thus blood bank
screening can provide an immediate source of anti-
endotoxin antibodies.
We are grateful to Mrs Maureen Rome for her
excellent technical work.
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APPENDIX 2
Antiendotoxin Antibody Specificities among African
and Caucasian Blood Donors in Natal
B. J. Vorster, Y. Jarvis, N. Badsha• and S. L. Gaffin'
Natal Blood Transfusion Service, Pinetown and 'Department of
Physiology, University of Natal Medical School, Durban.
Endotoxin, a lipopolysaccharide located on the outer surface of gram-
negative bacteria, is believed to be the major causative factor in the 50 01,
mortality in gram-negative sepsis, which results in c. 100 000 deaths per
year in the United States. Under certain conditions, endotoxin may enter
the systemic circulation from the intestine and cause additional shock and
mortality. We have shown that an otherwise lethal endotoxaemia, induced
by haemorrhage and resulting from intestinal endotoxin invasion, can be
reversed by the use of human antiendotoxin antibodies obtained by screen-
ing random blood units in a blood bank (Gaffin et al. (1981). J. surg. Res.
31, 18). The immunoprecipitin procedure employed as a screening test was
very slow and inefficient. We have now developed a rapid Enzyme Linked
I mmunosorbent Assay (ELISA) for detecting the presence of human anti-
endotoxin antibodies. Using this procedure some 100 000 blood units may
be screened in triplicate per year. In Natal, blood units containing high con-
centrations of specific antibodies ( > 40 pg/cm 3), were found with a fre-
quency of 3.6% among white donors (n = 1658) and 10.3% among African
donors (n 2482, P < 0.01). The white male and female donors showed no
significant differences, but the African women had almost twice the fre-
quency of high titre serum as the African men (14.43% versus 7.68%, P <
0.01).
Differential absorption experiments were carried out on selected scrum
samples. Sera were preineubated with one or several pure endotoxins prior
to determining quantitatively the antiendotoxin antibody activity remain-
ing in the absorbed sera on EL ISA plates coated with one or a mixture of en-
dotoxins. Serum samples were found to contain mixtures of antiendcsoxin
antibodies. Some of these antibodies cross-reacted with many, but not all,
endotoxins used, while other antibodies appeared to bind only one endo-
toxin.
Antibiotic Effect of Human and Equine Antiendotoxin
Antibody-rich Serum on Klebsiella pneumoniae
S. L. Gaffin, R. Ni. Robins-Brown•, R. Cooper', M. Gregory, N. Badsha,
J. Brock-Utne and B. J. Vorstert
Departments of Physiology and 'Microbiology, University of Natal
Medical School, Durban and tNatal Blood Transfusion Service, Pinetown.
The administration of endotoxin-specific antibodies improves survival in
gram-negative sepsis in a variety of animals and humans. We have in-
vestigated the bactericidal effects of human and equine antiendotoxin
antibody-rich serum samples. Human high titre serum ( > 40 Agicm 3) was
obtained by screening blood units in a blood bank by an Enzyme Linked
Immunosorbent Assay (ELISA) (Gaffin et at. (1982). Ann. cfin. Biochem.
in press). Equine serum was obtained by appropriate immunization of
horses. Serum samples were placed into wells of agar plates 'seeded' with
Klebsiella pneumoniae. Those wells containing high titre serum inhibited
growth around them.
Treating K. pneumoniae in vitro with antiserum caused the cells to 'ag-
glutinate' and form a sticky mass. This process required the presence of
complement. Electron microscopy showed that surface membranes of
Klebsiella were affected by the antiserum, leading to an increased
permeability, swelling, and lysis. Cell contents released from lysed bacteria
apparently caused the remaining membranes and cell components to adhere
together as a solid mass. The antiendotoxin antibody-rich serum does more





PRCELUTION AND PRCPE..‹....ES 3F HI/AAN MITaIDOTCXIN ANTIBODY RICH 3Ati4A CICEULIN.S.L.
GAFFIN, N.BACSEA, M. IFJ--rrRY, J.ERCCIC-UTNE,B.VCRS=, J.O0NRADIE. Dept. Ptysiology,
Univ. Natal. Medical School, Durban, and Natal Blood Transfusion Service, Pinetown.
South Africa.
Studies by Braide's Troup, McCahes' and Jones' have shown the protective effect
of huian antiendotoxin antibodies on gram negative sepsis and evdctcxerria in animals
and man. However, such antibodies are not available for general clinical use. We
found that simply screening the units of blood in a blood bank _an provide substan-
tial amounts of AntiET Ab rich human plasma (Gaffin et al., 1981.J.Surg.Res. 31:18)
which protracted cats from lethal endotoxemia caused by hemorragic shock. An
ELISA procedure has been used for larger scale screening (Oaffin et al. 1982.Ann.
Clin.Bicchem. In Press) and a garma globulin fraction (Lot LG-1) was prepared. The
total protein conc. is 16%, the antiET ab concentration is 1200 ...g/m1 and the
relative reactivities of these Ab's prepared from various bacteria is
100:24.5:10.4: 21.2: 46.8: 21.4: 9.5: 83.2: 13.8: 67.9: 29.3: 45.1: for Sh. flexmeri:
E toll 055E5: Ec 0127B8: Ec 021B12: Ec 0268.6 Cc 011124: S. minnesota, S. abortus
equi: S. marcescens: S. typhimurium: S. typhosa: S. entereditis, respectively.
This globulin together with caanplement could lyse and kill a range of gram negative
bacteria, including Klebsiella( Electron microscopic studies shod that with LG-1
and complement the rod anaped gram negative bacteria swell, become baloan shaped,
burst, release their cytoplasm and the membranes form ghosts. Clinical trials




PROP=IES OF HUMAN LPS SPECIFIC GAMMA GI0BULLN
N. Badsha,• B. 7crster• and S.L. Gaffin. Department Physiology, Lbuversity Natal
Mealral School, Durban and Natal Blood Transfusion Service, Pinetown, Natal, South
Africa.
We have produced huren LPS specific ganna globulin (Lot LG-1) currently under-
going clinical evaluation. BALB/C mice were inoculated i.p. with 0.1m of live
cultures of Pseudornonas aeruginosa (Type 214) or placebo LG-1 reduced mortality
from 75% to 8% and morbidity index frau: 58 to 16.
we previously tel..urted that Ab's in LG-1 bound to LPS fram a wide range of gram
negative bacteria. LG-1 was absorbed with various pure and mixtures of LPS prior
to ELISA measurement of remaining Ab activity on microtiter plates coated with one
or a mixture of LPS. This compared the relative amounts of various "specific" and
cross reacting anti LPS Abs present in LG-1.  76.8% of Abs birding Sh.flexneri were
specific, 56.5% to E.coli 026:86, 33.4% to E.coli 0111:84, 21.8% to S.typhimurium.
The remainders of Anti LES bindings •.ere "cross reactive'.  Only 0-15% specific
'DU-ed.-1g was seen in Abs to E.coli 055:B5, 0127:88, 0128:B12, S.marcescens,
S.ab.equii, S.enteretidis, S.typhosa and S.minnesota.  Presumably the relative
abundance of Abs in LG-1 reflects previous infections.  ticmever Ab's binding to
3n.fleKneri ...ere most glundant in LG-1, tut Shigella isolates were <1% of total.
KlebsielLa binding Ab's 10.1% of LO-1 but 29.1% of total isolates.
APPENDIX 6
PROPERTIES OF HUMAN ANTILIPOPOLYSACCHARIDE (ANTI-LPS)






, N. BADSHA, B.J. VCRSTER
1. From the Department of Physiology, University of Natal,
Faculty of Medicine, Durban and Natal Blood Transfusion
Service, Natal, South Africa
Running Title: ANTI-LPS SPECIFIC GLOBULIN
44 Supported by grants from SA MRC and Anglo American Corporation
* Address for all correspondence and reprint requests:
Dr S L Gaffin
Department of Physiology
University of Natal




Blood donated to the Natal Blood Transfusion Service was screened
by an ELISA for Anti-LPS antibodies.  Plasma units with high
concentrations ( >40,pg/m1) of Anti-LPS IgG were pooled and
fractionated to obtain a gamma globulin (Lot LG-1). The
binding of LG-1 antibodies to LPS prepared from 14 bacterial
species and strains was found to be the highest to LPS from
Shigella flexneri, S. abortus equi  and S. typhimurium and
intermediate with Klebsiella pneumonia, Pseudomonas aeruginosa,
S. enteritidis and E. coli 026:B6. Differential absorption
experiments showed that LG-1 contained a mixture of specific
and cross-reacting antibodies. A large proportion of antibodies
binding to Shigella flexneri LPS were mainly specific, while
those binding to S. typhimurium and the other Salmonella species
tested were largely cross-reactive. There was little correlation
between the spectrum of activity of the LG-1 antibodies and the
incidence of gram negative bacteria in blood cultures taken from
hospital patients in an area covered by the Transfusion Service.
Mice treated with LG-1 prior to inoculation with Pseudomonas 
aeruginosa were significantly protected against morbidity and
mortality compared to controls.
2.
LNTRODUCTION
It is increasingly recognised that a major component of mortality
and morbidity in gram negative septicaemia and nonseptic shock
is the lipopolysaccharide, (LPS, endotoxin) released from the
surface of gram negative bacteria, or which may enter from the gut
where it is always present
(1,2)
. With conventional antibiotic
therapy alone mortality in such cases is approximately 30-50 per cent;
in part because the LPS remains toxic even though the bacteria
which produced it are dead
(3)
. The administration of specific
anti-endotoxin antibodies has significantly reduced this high
mortality and morbidity in animals and man (4,5,6,7,8)
Unfortunately, substantial quantities of human anti-lipopolysaccharide
(Anti-LPS) are not presently available for clinical use, in part
due to logistic, ethical and legal problems involved in immunizing
volunteers with a potentially toxic substance. We partially solved
this problem by recognizing that significant numbers of blood units
donated to a blood bank contain raised levels of Anti-LPS
antibodies (6) , developing an ELISA procedure to rapidly screen
donated blood, retaining and pooling those units with high concentra-
tions of Anti-LPS
(9)
. Such human Anti-LPS was protective in
animals against septic abortion (10) and in humans against septic
shock (7,11) . We report here on the properties of a gamma globulin
(Lot LG-1) prepared from such high titre human plasma.
3.
MATERIALS AND METHODS
1. PREPARATION: ANTI-LPS SPECIFIC GAMMA GLOBULIN
An ELISA was used to measure Anti-LPS in all studies reported
here
(9)
. This ELISA had been calibrated by an immanoprecipitin
procedure
(6)
. The ELISA was performed in microtitre plates
which had been precoated with a mixture LPSs prepared by the
Westphal extraction procedure (SIGMA) from the following bacteria:
E. coli 0127:B8, E. coli 0128:B12, E. ooli 0111:B4, E. coli 026:B6,
S. minnesota, Shigella flexneri, S. abortus equi, S. marcescens,
S. typhosa, S. typhimurium and S. enteritidis. Blood donated
to the Natal Blood Transfusion Service, Pinetown, South Africa
was routinely screened for the presence of Anti-LPS IgG, usually
within three days of donation. Those units containing LPS-
precipitible antibodies at concentrations greater than 40yg/ral
were stored frozen at -20 °C until 50 litres accumulated. This
plasma was pooled and fractionated at the National Blood Fractionation
Centre according to.a standard licensed procedure using Kistler
modification of the Cohn method
(12) 
and glass ampules were filled
with this gamma globulin labelled Lot LG-1. Before use, Lot LG-1
underwent the normal quality controls applicable to all gamma
globulin preparations.
2. RELATIVE ACTIVITY OF LG-1 ANTIBODIES
LG-1 was diluted 1:800 in 0.1M NaC1 containing 0.5M Tris adjusted
to pH 8,0 and also containing 2% each of sheep and bovine serum.
The assay was carried out on microtitre plates coated with only
one each of the following endotoxins: E. coli 055:B5;
E. coli 0127:B8; E. coli 0128:B12; E. coli 0111:B4; E. coli 026:B6;
S. minnesota; Shigella flexneri; S. abortus equi; S. marcescens;
S. typhosa; S. typhimurium; S. enteritidis; Klebsiella pneumonia 
and Pseudomonas aeruginosa. Several wells on every plate were
coated with LPS from Shigella flexneri to use as a reference
standard.
4.
3. DIFFERENTIAL ABSORPTION EXPERIMEt1TS
DG-1 was preincubated with a variety of solutions containing LPS
and then tested for antibody activities remaining.  LG-1 was
diluted 1:800 in 0,1M NaC1 containing 0.5M Tris adjusted to
pH 8,0 and also containing 2% each of sheep and bovine serum.
This solution was used in the following incubations below, all
carried out at 37 °C for 10 minutes. In each case endotoxin
was added to a final concentration of 50yg/ml.
(i) The diluted LG-1 was incubated separately with each
LPS prepared from the same bacteria as described
Above in 2 omitting K. pneumoniae and P. aeruginosa.
(ii) Diluted LG-1 was incubated with a mixture of all
twelve endotoxins, each at a concentration of
4,16 )pg/ml.
(iii) Diluted LG -1 was incubated with mixtures of eleven
of the twelve LPS by omitting each one in turn.
(iv) As controls the diluted LG-1 was incubated with
0,1M acetate buffer, pH 5,0 (the LPS buffer).
The Above absorbed LG-1 were centrifuged at 4°C for three minutes at
16 000 x g. They were then assayed for Anti-LPS IgG. The assay
was carried out on two types of microtitre plates : those coated
with only one of each of the first 12 of the above LPS separately,
and those coated with a mixture of all of the first 12 LPS,
together.
4. MOUSE PROTECTION STUDIES
Each of twelve Baib C mice matched for weight received either
0,1 ml of 0,15M NaC1 or 0,1 ml LG-1 intraperitoneally.  One hour
later all mice were inoculated with 1,0 ml of a suspension of
Pseudamonas aeruginosa type P14 containing 1,1 x 10
9 
organisms/ml .
* A gift of Dr R J Jones, Accident Hospital, Birmingham, U K.
5.
They were placed in separate cages and classified at 2 hourly
intervals by an experienced animal handler from 0 = no change,
healthy,to + 5 = prostrated, breathing, to + 6.death.  Mice




The ELISA colour development, and hence the binding, of LG-1
antibodies to lipopolysaccharide prepared from 14 species and
strains is shown in Fig. 1. Binding was found to be highest
to LPS from Shigella flexneri, S. abortus equi and S. typhimurium,
and at intermediate levels with S. enteritidis, K. pneumoniae and
P. aeruginosa and E. coli 026:86. Binding to the other LPS
was relatively low.
Differential absorption experiments show that LG-1 Anti-LPS
antibodies are a mixture of cross-reacting as well as specific
antibodies. This is illustrated (Fig. 2) by the following
examples :
LG-1 was first incubated with LPS prepared from Shigella flexneri 
and then assayed on plates which had been coated with all 12 LPS.
The colour developed in the ELISA procedure for this Shigella 
preincubated sample was found to be only 60% of that of the
untreated control, i.e. of the colour developed by all antibodies
in LG-1 binding to all 12 endotoxins coating the plate. Forty per
cent of the colour was lost by absorption of LG-1 by Shigella 
flexneri endotoxin. LG-1 was then preincubated with a mixture
of the other eleven LPS excluding Shigella flexneri endotoxin.
In this case the colour developed was 30,7% of the untreated
control. This 30,7% represents colour produced by those antibodies
reacting specifically with Shigella flexneri endotoxin and not
absorbed out by any of the other endotoxins being tested. The
remaining antibodies (9,3%) were cross-reactive.
When LG- 1 was incubated with Shigella flexneri and then assayed
on plates coated only with Shigella LPS, the activity was reduced
to only 6,1% of the untreated control. However, when LG-1 was
preincubated with the other 11 LPS still 91,7% of the activity was
retained. In this latter case antibodies which bound to only
7.
Shigella flexneri LPS were not absorbed out and these could bind
to the Shigella flexneri LPS coating the plates. Thus a large
proportion of antibodies binding to Shigella flexneri were mainly
specific, but with some cross-reactivity. (See Fig. 2). Comparable
results were obtained with E. coli 026:B6 LPS; of these, however,
approximately half are specific and half cross-reacting.
A very different set of results was seen with S. typhimurium.
48,86% of the total antibodies were found to bind to Salmonella 
typhimurium LPS. When LG-1 was incubated with the other 11 LPS,
omitting S. typhimurium, the colour developed on the 12 LPS plates
was reduced to only 10,67% of the untreated control.  Similarly,
when this preincubated sample was assayed on plates coated only
with S. typhimurium LPS, the activity was reduced to 10,5% of the
untreated control. Apparently most of the antibodies in LG-1
Which react with S. typhimurium LPS also bind to the other LPS
added to the incubation mixture and therefore have been absorbed
out, leaving the relatively few specific antibodies, which bind
to the S. typhiumurium LPS coating the plates. From these experiments
it is concluded that the antibodies binding to S. typhimurium are
largely cross-reactive (78,16%), with the balance probably being
specific.
From Fig. 2 it can be seen that the antibodies which bind the LPS
of all the other Salmonella species tested (S. abortus equi;
S. enteritidis; S. typhosa; S. minnesota)  are also largely cross-
reactive.
LG-1 antibodies to LPS prepared from Serratia marcescens, E. coli 
0128:B12 and E. coli 0111:B4 are also mainly cross-reacting.
Endotoxins from E. coli 055:B5 and E. coll. 0127:B8 are bound only
by cross-reacting antibodies.  For example 6,9% of the total
antibodies bind E. coli 055:B5 LPS. When LG-1 was incubated
with the other 11 LPS except E. coli 055:B5 LPS, the activity on
the 12 LPS plates was reduced to zero, i.e. there are no antibodies
which exclusively bind to E. coli 055:B5 LPS.




There were marked differences between the groups of mice given
placebo or LG-1 after inoculation with Pseudomonas culture
(P14) (Fig. 3). The morbidity curve of the controls reached
half its maximum plateau value within five hours and its maximum
plateau value within 24 hours. The LG-1 pretreated mice
showed only slight morbidity at 18 hours which then subsided
until 40 hours postinoculation. Its final value was only 16
arbitrary units compared to the controls' 58. The first
death of the control mice occurred 18 hours after inoculation
and 50% had died by 36 hours postinoculation. On the other
hand the LG-1 treated mice had a very low mortality (1/12)
occurring after 50 hours postinoculation.
9.
DISCUSSION
LG-1 was prepared by the screening of approximately 3000 plasma
units resulting in 50 litres of high titre plasma.  We previously
found that each donor had his own particular group of antibodies
which bound various LPS to a different extent - one donor having
high levels of antibodies against, say, E. coli 055:B5,another
to Sh. flexneri and another to S. typhosa
(9)
. The final product
LG-1 thus contains antibodies to the LPS of a wide range of
different gram negative bacteria.
Anti-LPS hyperimmune serum and plasma have been shown to reduce
mortality and morbidity in a wide range of gram negative bacterial
infections and endotoxaemias in animals and man
(4-8)
. Because
of its beneficial effect in endotoxin and mediated diseases, equine
Anti-LPS has become almost a routine therapy in the equine
veterinary industry in South Africa
(13)
A question remains as to whether there are present in our LG-1,
anti-gram negative bacterial antibodies other than those specific
to LPS which also contribute to the observed beneficial effect of
LG-1 on mortality and morbidity in the infected mice.  At present,
this possibility cannot be excluded. A controversy persists as
to the therapeutic advantage of an IgM rather than an IgG preparation (4) .
We and others found an IgG preparation to be therapeutic against:
Pseudomonas lethality in mice, endotoxin shock induced by prolonged
haemorrhage in cats
(6)
, septic abortion in pregnant rats
(10)
, and
infections in mice (14) and humans (15) with large burns. IgG
has the benefits of having a substantially longer half-life in
circulation and ease of preparation compared to IgM.
An important problem has been how to prepare human Anti-LPS on a
substantial scale for human use.  For a period of two years a
monthly incidence of 6,8 - 7,2% of donated blood had high concentra-
tions (40> jig/ml) of Anti-LPS IgG. For a blood bank collecting
200 units per day this yield provides 7% x 200/day x 5 days/wk x
50 weeks = 3500 Anti-LPS rich plasma units per year. Our experience
10.
is that the antibodies in approximately six units of such plasma
are therapeutic for severe gram negative septic shock in humans
(11)
Therefore 480 adult doses can be prepared per year. Due to the
long shelf life of gamma globulin, it can be stored well for
emergency use. It may be used with fewer licensing problems as
a freeze dried plasma. Ultimately, an intravenous form of the
gamma globulin should be prepared because of the importance of
immediate availability of the antibodies for patients in shock.
Inevitably, however, such procedures deplete those protective
LPS specific antibodies in the general pool of the low titre gamma
globulin.
The reason why certain donors have high levels of Anti-LPS is not
known but is expected to be due in part to the donor having had
a recent subclinical infection. An attempt was made to relate
the relative binding activities of LG-1 antibodies to the reported
incidence
(16) 
of various gram negative bacteria in blood cultures
in hospital patients in the area in which blood is donated.
It is seen in Fig. 4 that in most cases the incidence of blood
cultures is not correlated with the binding of the antibodies
to various LPS. For example LG-1 is high in IgG binding to
Sh. flexneri but the incidence of Sh. flexneri in blood cultures
is virtually nil. The incidence of S. typhosa in blood cultures
is high, yet binding of LG-1 antibodies towards S. typhosa LPS
is relatively low. In contrast, antibodies abundant towards most
of the other Salmonella species; these species, however, are far
less commonly encountered in blood cultures.  In the case of
E. coli and Pseudoironas there was some similarity between antibody
activity and their incidence in blood cultures.
•
Shigella is a common cause of intestinal infection but rarely
gives rise to bacteraemia; the anti-shigella antibodies reported
here may be important in restricting the growth of this species in
the bloodstream and preventing bacteraemia. There appears to be
a limitation to the number of strains capable of causing bacteraemia
and one of the limiting factors may be the amount and specificity
of the Anti-LPS antibodies present in the host's plasma. Further
epidemiological studies are needed for a deeper understanding of
the Anti-LPS antibody specificity. For instance there may be
a high correlation between stool isolates and specific Anti-LPS
concentration.
We routinely produce human LPS specific globulin and anti-LPS freeze
dried plasma with the facilities of a medium sized blood bank.
The Anti-LPS IgG binds to a wide range of gram negative bacteria,
was protective against pseudomonas bacteraemia in mice, and was
previously found to be protective against E. coli induced abortion
in pregnant rats
(10)
. Such preparations may be valuable adjuncts
to conventional antibiotic therapy in septicaemia
(4,5,7,11)
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LEGENDS
Figure 1 The Relative Binding Capacities of IgGs present in
human LPS specific globulin (LG-1) to lipopolysaccharides
prepared from 14 bacterial species and strains.
Figure 2 The Specificities of LG-1 antibodies to LPSs prepared
from 12 bacterial species and strains.  Except for
Sh. flexneri, most showed considerable cross
reactivity.
Figure 3 Morbidity and Mortality in Pseudomonas infected mice.
Mice received 0.1 cc i.p. of LG-1 (Solid Symbols)
or 0.9% NaC1 (Open Symbols). One hour later they
were infected with Pseudomonas (10
9 
org.). Both
the Morbidity Index (Circles) and the Mortality (Squares)
of LG-1 treated mice were less than those in the
controls.
Figure 4 Comparison of LG-1 activity and the frequency of
hospital isolates.
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